Patent Grant
10493199
The present disclosure relates generally to fluid delivery devices and particularly to fluid delivery devices capable of delivering one or more medicaments to a patient to provide a sustained, basal delivery and/or a bolus delivery of each medicament.
Fluid delivery devices, such as ambulatory infusion pumps, for example, have been developed for delivering liquid medicaments to a patient. Many such pumps or drug delivery devices are able to provide both steady state delivery (“basal delivery”) and instantaneous bursts of a predetermined amount of drug (“bolus delivery”) as required. In many instances, it is beneficial to provide a basal delivery of a drug which may be supplemented by a bolus delivery as well. For example, insulin for diabetes treatment as well as patient controlled analgesia for chronic pain treatment may be administered both at a continuous basal rate of delivery as well as via bolus amounts of delivery. Many such drug delivery devices are compact and able to be fixed to the user or patient during use and subsequently disposed of when the treatment is finished.
Many attempts have been made to provide continuous or near continuous basal delivery of such medicaments using various pump systems. The accuracy of the basal delivery rate often varies when the volume of the drug being delivered is small. Many fluid delivery devices include a reservoir to contain the liquid medicament and use various mechanical, gas, or electromechanical pumping or metering technologies to deliver the medicament to the patient via a needle or other catheter inserted transcutaneously, or through the skin of the patient.
The present invention comprises one or more of the features recited in the appended claims or the following features or combinations thereof:
According to one aspect of the disclosure, a fluid delivery device for administering a first medicament and a second medicament is provided. The fluid delivery device may function to administer a basal delivery of the first medicament and/or a basal delivery of the second medicament. Further, the fluid delivery device may function to administer a bolus delivery of the first medicament and/or a bolus delivery of the second medicament. In other words, any combination of basal and/or bolus deliveries of each of the first and second medicaments is contemplated.
Various configurations of basal drive mechanisms of the fluid delivery device may provide the basal delivery of the first and/or second medicament. For example, one basal drive mechanism may provide the basal delivery of only the first medicament, only the second medicament, or both the first and second medicaments. In instances where the basal drive mechanism provides the basal delivery of only one of the first and second medicaments, a second basal drive mechanism of the fluid delivery device may provide the basal delivery of the other medicament.
Similarly, various configurations of bolus drive mechanisms of the fluid delivery device may provide the bolus delivery of the first and/or second medicament. For example, one bolus drive mechanism may provide the bolus delivery of only the first medicament, only the second medicament, or both the first and second medicaments. In instances where the bolus drive mechanism provides the bolus delivery of only one of the first and second medicaments, a second bolus drive mechanism of the fluid delivery device may provide the bolus delivery of the other medicament.
According to another aspect of the present disclosure, the fluid delivery device may include one or more needles in fluid communication with the first and second reservoirs containing the first and second medicaments. For example, a first needle may be in fluid communication with the reservoir containing the first medicament while a second needle may be in fluid communication with reservoir containing the second medicament. Such needles may be spaced-apart from each other or positioned on opposite ends of the fluid delivery device to substantially prevent any mixing of the first and second medicaments during delivery. Further, one needle may include a delivery arm (for subcutaneous insertion into the patient's skin) which is longer than a delivery arm of the other needle. In such a case, one of the first and second medicaments will be delivered to a subcutaneous depth greater than the other one of the first and second medicaments. Delivering the medicaments to a different depth may also substantially prevent any mixing of the first and second medicaments.
According to still another aspect of the present disclosure, a single needle may be provided which is in fluid communication with each reservoir of the first and second medicaments. Such a needle may be “Y-shaped” and include a first uptake arm for fluid communication with the reservoir containing first medicament and a second uptake arm for fluid communication with the reservoir containing the second medicament. Each of the first and second uptake arms of the needle may be in fluid communication with a delivery arm of the needle such that the first and second medicaments may mix with each other within the delivery arm of the needle prior to being delivered into the patient.
Illustratively, a fluid delivery device of the present disclosure may include an exterior housing, a first reservoir within the housing configured to contain the first medicament, and a second reservoir within the housing configured to contain the second medicament. The fluid delivery device may further include a needle having a first end configured for fluid communication with the first reservoir and a second end configured to extend exteriorly from the housing. Alternatively, the needle may include a third end configured for fluid communication with the second reservoir containing the second medicament. The fluid delivery device may further include a second needle having a first end configured for fluid communication with the second reservoir and a second end configured to extend exteriorly from the housing. The first needle may be positioned at a first end of the housing while the second needle may be positioned at a second end of the housing. Further, a delivery arm of the first needle may be longer than a delivery arm of the second needle.
Further illustratively, the fluid delivery device may include a basal drive mechanism for providing a basal delivery of the first medicament. The same basal drive mechanism may also provide a basal delivery of the second medicament. Alternatively, a second basal drive mechanism may provide the basal delivery of the second medicament. In either case, the basal drive mechanism may include a coil spring, a basal drive piston, and a hydraulic fluid reservoir. Further, the fluid delivery device may include a first pump chamber associated with the first medicament in fluid communication with the hydraulic fluid reservoir of the first basal drive mechanism via a first flow restrictor. Similarly, a second pump chamber associated with the second medicament may be in fluid communication with the hydraulic fluid reservoir of the second basal drive mechanism via a second flow restrictor.
Further illustratively, a first delivery piston of the fluid delivery device may be positioned within the first fluid reservoir to exert a force on the first medicament within the first fluid reservoir. Similarly, a second delivery piston may be positioned within the second fluid reservoir to exert a force on the second medicament within the second fluid reservoir.
The fluid delivery device may further include a bolus drive mechanism for providing a bolus delivery of the first medicament. The same bolus drive mechanism may also provide a bolus delivery of the second medicament. Alternatively, a second bolus drive mechanism may provide the bolus delivery of the second medicament. In either case, the bolus drive mechanism may include a ratchet and a bolus piston coupled to the ratchet. A pump chamber of the fluid delivery device is associated with the first fluid reservoir and the bolus piston is positioned within a bolus fluid reservoir in fluid communication with the pump chamber.
According to another aspect of the present disclosure, a method of administering first and second medicaments from an fluid delivery device includes delivering a first basal delivery of the first medicament, and delivering a second basal delivery of the second medicament. The first basal delivery may be approximately equal to the second basal delivery. Alternatively, the first basal delivery may be greater than the second basal delivery.
Illustratively, delivering the first medicament may include actuating a first basal drive mechanism and delivering the second medicament may similarly include actuating the first basal drive mechanism. Alternatively, delivering the second medicament may include actuating a second basal drive mechanism different from the first basal drive mechanism.
The method may further include delivering a first bolus delivery of the first medicament and delivering a second bolus delivery of the second medicament. The first bolus delivery may be the same as the second bolus delivery. Alternatively, the first bolus delivery may be greater than the second bolus delivery.
Illustratively, delivering the first bolus delivery may include actuating a first bolus drive mechanism and delivering the second bolus delivery may include actuating the first bolus drive mechanism. Alternatively, delivering the second bolus delivery may include actuating a second bolus drive mechanism different from the first bolus drive mechanism.
According to still another aspect of the present disclosure, another method of administering first and second medicaments from a fluid delivery device includes (i) forcing hydraulic fluid from a hydraulic fluid reservoir into a first pump chamber to exert a force on a first movable barrier, (ii) forcing hydraulic fluid from the hydraulic fluid reservoir into a second pump chamber to exert a force on a second movable barrier, (iii) exerting a force on a first piston to expel at least a portion of the first medicament through an aperture of the first fluid reservoir, and (iv) exerting a force on a second piston to expel at least a portion of the second medicament through an aperture of the second fluid reservoir.
Illustratively, forcing the hydraulic fluid from the hydraulic fluid reservoir may include applying a spring force to a piston within the hydraulic fluid reservoir. Forcing the hydraulic fluid from the hydraulic fluid reservoir may further include forcing hydraulic fluid from the hydraulic fluid reservoir through a flow restrictor and into the first and second pump chambers.
The fluid delivery devices described herein may be used to delivery a wide variety of drugs, pharmaceutical agents, and medicaments, and other components useful for treating diseases and disease states. In one embodiment, the delivery devices described herein include or are configured or adapted to include pre-selected medicaments in the corresponding reservoirs. In one aspect, the pre-selected medicaments are used to treat diabetes and/or diabetic conditions. In another aspect, the pre-selected medicaments are used to treat bacterial infections and/or other diseases associated with pathogenic cell populations. In another aspect, the pre-selected medicaments are used to treat diseases associated with neurotransmitter dysfunction, including but not limited to diseases that are treatable with dopamine and/or compounds that function as dopamine agonists and/or dopamine antagonists.
The above and other features of the present disclosure will become apparent from the following description and the attached drawings.
The detailed description particularly refers to the accompanying figures in which:
b are schematics showing dual-cartridge drug delivery devices of the present disclosure which provide a basal delivery of both first and second medicaments and which provide a bolus delivery of both first and second medicaments;
Looking first to
It should be appreciated that the fluid delivery devices described herein each include an outer or exterior housing (not shown). The structures shown in
Looking now to
First and second needles 32, 34 of the drug delivery device 10 each include a first end 36 and a second end 38. The first end 36 of each needle 32, 34 is received through an outer wall of the respective first and second stoppers 24, 28 for positioning within the hollow chamber 26 of each stopper 24, 28. The second end 38 of each needle 32, 34 is provided for subcutaneous insertion into a patient in order to deliver the first and second medicaments 20, 22 to the patient. Illustratively, the first and second needles 32, 34 are shown to define a “J-shape” such that each needle 32, 34 includes an uptake arm 40 and a delivery arm 42 which are generally parallel to each other and a transverse arm 44 connecting the uptake and delivery arms 40, 42 together. Each arm 40, 42, 44 of each needle 32, 34 is cannulated to provide a generally continuous J-shaped passageway to allow the respective first and second medicaments 20, 22 to travel from the first end 36 of each needle 32, 34 to the second end 38 of each needle 32, 34.
As shown in
Looking again to
A driven or delivery piston 58 of the drug delivery device 10 is positioned within the inner chamber of the reservoir 12 and operates as a partition or movable barrier between the first medicament 20 contained within the first drug reservoir 12 and the hydraulic fluid contained within the pump chamber 56. Illustratively, the hydraulic fluid contained within the pump chamber 54 and the basal fluid reservoir 52 is an oil (not shown), or particularly a silicone oil, for example. However, these chambers may be filled with other non-compressible fluids as well such as those disclosed in U.S. Patent Application Publication US 2005/0119618, the disclosure of which is hereby incorporated by reference herein.
In operation, the coil spring 48 of the first basal drive mechanism 46 slowly expands to exert a bias on the basal drive piston 50 thereby exerting a force on the hydraulic fluid within the basal fluid reservoir 52 and the pump chamber 54. Such an increase in fluid pressure within the pump chamber 54 urges the delivery piston 58 to the right (as viewed in the orientation of
The drug delivery device 10 further includes a second basal drive mechanism 60 which provides a basal delivery of the second medicament 22 to the patient. The second basal drive mechanism 60 is the same as or similar to the first basal drive mechanism 46. As such, like reference numerals have been used to denote like components. For example, the second basal drive mechanism 60 includes the coil spring 48 secured to the basal drive piston 50. The basal fluid reservoir 52 of the second basal system is in fluid communication with the pump chamber 54 through the connective passageway or flow restrictor 56. Similarly, the fluid reservoir 52, pump reservoir 54, and flow restrictor 56 associated with the second medicament are each filled with an oil such as a silicone oil, for example. Further, the second basal drive mechanism 60 operates the same as or similarly to the first basal drive mechanism 46 to force the second medicament 22 from within the second reservoir 14 through the needle 34 and into a patient.
As discussed above, the fluid delivery device 10 includes two separate basal drive mechanisms 46, 60 to provide a basal delivery of each of the first and second medicaments 20, 22. In operation, a single button or actuator may be activated by a user to actuate both of the first and second drive mechanisms 46, 60 at one time. Of course, separate actuators may be used to independently actuate each of the drive mechanisms 46, 60 as well. Illustratively, such button(s) or actuator(s) may be located on or within the outer housing (not shown) of the fluid delivery device 10 to be activated by a user or patient.
Looking still to
In operation, a force applied to the toothed rack 66 advances the dual-head piston assembly 70 to force fluid from each bolus fluid reservoir 80 into the respective pump chamber 54 to move the respective driven piston 58 thereby causing bolus delivery of both the first and second medicaments 20, 22 from the respective first and second drug reservoirs 12, 14. A bolus actuator button may be coupled to the toothed rack 66 such that when a user depresses the bolus actuator button, the toothed rack 66 is advanced a pre-determined distance. Alternatively, such a bolus actuator button may be coupled to the pawl 68 such that when a user depresses the bolus actuator button, the pawl 68 is advanced a predetermined distance and forces the toothed rack 66 to advance the same predetermined distance as well. With such an arrangement, a secondary mechanism may be used to retract the pawl 68 relative to the toothed rack 66 to an activated position such that the pawl 68 may be advanced again to provide another bolus delivery. In either case, the pawl 68 of the ratchet 64 prevents the toothed rack 66 from moving backward after having been advanced. Further, the pawl 68 of the ratchet 64 prevents the toothed rack 66 from moving backward due to any increased fluid pressure caused by fluid moving from the basal fluid reservoirs 52 into the pump chambers 54, for example.
As described above, the fluid delivery device 10 includes two separate fluid reservoirs 12, 14 containing two different medicaments 20, 22 therein. Illustratively, separate needles 32, 34 are provided to deliver each medicament 20, 22 to a patient. However, it is within the scope of this disclosure to include a single needle for delivering each of the first and second medicaments 20, 22. Such embodiments are discussed in greater detail below.
Looking now to
In other words, the concerted movement of the pistons 78, 178 operates to displace a different amount of fluid from the respective bolus reservoirs 80, 180 to act on the driven piston 58 associated with each of the first and second reservoirs 12, 14. This causes a greater pressure to be exerted on the piston 58 associated with the reservoir 12 relative to the pressure associated with the reservoir 14. This in turn causes a larger bolus delivery of the first medicament 20 to be delivered relative to the bolus delivery of the second medicament 22. Therefore, an incremental movement of the dual-head piston assembly 70 of the bolus drive mechanism 62 will cause a greater amount of the first medicament 20 to be delivered to the patient than the second medicament 22.
In many instances, for example, it may be preferable to deliver a first amount of a first medicament with a second amount of a second medicament. Varying the size of the bolus drive piston, therefore, allows the ratio of the two medicaments delivered in a bolus delivery to be varied. In other words, it is within the scope of this disclosure to vary the size of the bolus pistons of the fluid delivery devices described herein in order to achieve any desired bolus delivery ratio between the two medicaments being delivered to a patient.
As is discussed in greater detail below, the size of other components associated with the fluid delivery device (e.g., drive pistons, flow restrictors, etc.) may also be varied in order to basally deliver the first medicament at a different rate than the second medicament. Again, any of these dimensions may be configured in order to produce a desired ratio between the basal delivery rates of the first and second medicaments.
Looking now to
In operation, the bolus drive mechanisms 280, 282 may, therefore, be actuated independently to separately advance each of the toothed racks 66 of the separate bolus drive mechanisms 280, 282 enabling a user to provide one bolus delivery of one of the medicaments 20, 22 without providing a bolus delivery of the other medicament 20, 22. For example, actuation by a user of the first bolus drive mechanism 280 provides a bolus delivery of only the first medicament 20 while actuation of the second bolus drive mechanism 282 provides a bolus delivery of only the second medicament 22. Of course, the bolus drive mechanisms 280, 282 may also be actuated by a single actuator (not shown) which is able to advance each of the toothed racks 186 at the same time.
Looking now to
The single basal drive mechanism 346 of the fluid delivery device 310 drives the basal delivery for both the first and second medicaments 20, 22. Thus, actuation of the drive mechanism 346 to permit the coil spring 48 to advance the basal drive piston 50 will cause both of the driven pistons 58 to advance as well. Illustratively, the size (including diameter, or width, and length) of each of the flow restrictors 356, 358, the pump chambers 54, the pistons 58, and the drug reservoirs 12, 14 are shown to be generally the same. As such, the rate of basal delivery of the first and second medicaments 20, 22 will generally be the same or similar. However, it should be appreciated that varying one or more of the dimensions of one or more of the aforementioned components associated with either medicament 20, 22 will provide a fluid delivery device which is capable of delivering the first medicament 20 at a first basal delivery rate while the second medicament 22 is delivered at a second basal delivery rate different from the first basal delivery rate. In such a scenario, these differing basal delivery rates are provided with the use of a single basal drive mechanism.
According to another aspect of the present disclosure, a fluid delivery device (not shown) similar to the fluid delivery device 310 of
As such, the drive mechanism operates to expel hydraulic fluid, such as silicone oil, for example, from the basal fluid reservoir, through the flow restrictor, and into the pump chamber to act upon the tail end of the Y-shaped piston. This force on the Y-shaped piston causes the piston to thereby expel the first and second medicaments 20, 22 from the reservoirs 12, 14. In such a fluid delivery system, a single bolus drive mechanism may also actuate bolus delivery of each of the first and second medicaments. Further, piston arms having a different size or different cross-sectional surface area relative to one another provides for a different basal delivery and a different bolus delivery between the two medicaments 20, 22.
Illustratively, the fluid delivery device 310 shown in
Further, a fluid delivery device 450, shown in
As discussed above, each of the fluid delivery devices 10, 110, 210, 310, 410, and 450 are able to provide both a basal delivery and a bolus delivery of the first medicament 20 as well as both a basal delivery and a bolus delivery of the second medicament 22. This function may be accomplished through various combinations of various features of these devices 10, 110, 210, 310, 410, and 450. For example, the fluid delivery device 10 includes two separate basal drive mechanisms and a single bolus drive mechanism able to provide a bolus delivery of each of the first and second medicaments 20, 22. The fluid delivery device 210 of
As noted above, the fluid delivery device 110 of
Looking now to
Looking first to
Looking now to
Looking first to
Similar to the fluid delivery device 710, the fluid delivery device 810 shown in
Further illustratively, the basal drive mechanism 846 is positioned between the pump chambers 54 and the first and second drug reservoirs 12, 14 containing the first and second medicaments 20, 22. As such, neither flow restrictor 856, 858 is positioned upstream or downstream from the other. While the single basal drive mechanism 846 is provided, it is also within the scope of this disclosure for the fluid delivery device 810 to include the single basal drive mechanism 346 shown in
Looking now to
Looking now to
Looking now to
The fluid delivery devices 10, 110, 210, 310, 410, 510, 550, 610, 710, 810, 910, 1010, 1310, and 1410 described above each include one or more of the basal fluid reservoirs 52, 352 fluidly coupled to one or more pump chambers 54 by a flow restrictor, such as flow restrictors 56, 356, 357, 358, 856, 858. Illustratively, the fluid reservoirs 52, 352 each define an inner chamber wherein the respective basal drive piston 50 of the particular basal drive mechanism is positioned within the inner chamber. However, other various basal fluid reservoirs which in fluid communication with one or more pump chambers may be provided as well. For example, looking to
Looking specifically to
As shown in
Illustratively, any of the fluid delivery devices disclosed herein may include basal and/or bolus drive mechanisms including a hinged plate member and a compressible fluid reservoir such as that shown in
Looking now to
Illustratively, the flexible member 1658 as well as the piston 58 described in previous embodiments operate as barrier mechanisms between the one of the medicaments 20, 22 and the hydraulic fluid exerting pressure onto the barrier mechanism. Although the piston 58 and the flexible member 1658 have been specifically disclosed herein, it is within the scope of this disclosure to include other such suitable barrier mechanisms separating the medicament 20, 22 from the hydraulic fluid. At least a portion of such barrier mechanisms are capable of moving within the inner chamber of the fluid reservoir relative to the outer walls of the fluid reservoir in order to force medicament out of the fluid reservoir. Various other barrier mechanisms are described in greater detail in U.S. Pat. No. 6,969,324 and U.S. Patent Application Publication No. US 2005/0119618, the disclosures of which are hereby incorporated by reference herein.
Each of the fluid delivery devices described above includes a first needle 32 in fluid communication with the reservoir 12 containing the first medicament 20 and a second needle 34 in fluid communication the reservoir 14 containing with the second medicament 22. These separate needles 32, 34 may be spaced-apart from each other a desired distance in order to prevent any mixing or commingling of the first and second medicaments 20, 22 once the medicaments are introduced subcutaneously into the patient. It is often desirable, for example, to prevent any mixing of two different medicaments before delivery, during delivery, and after delivery of the medicaments into the patient if and when there may be compatibility issues between the two medicaments, for example. As such, the needles 32, 34 may be positioned at opposite ends of the respective fluid delivery device in order to maximize the distance between the two medicaments when each is delivered into the patient.
Additionally, or as an alternative, the first needle 32 may be provided with a delivery arm 142 which is significantly longer than the delivery arm 42 of the second needle 34, as shown in
Illustratively, therefore, separate needles 32, 34 may be used to separately deliver the first and second medicaments 20, 22. In instances where there may be compatibility issues between the two medicaments 20, 22, the needles 32, 34 may be spaced-apart from each other a suitable distance to substantially prevent any mixing of the medicaments 20, 22 during and after delivery of the medicaments 20, 22 to the patient. Additionally, or as an alternative, the needles 32, 34 may be inserted into the patient at different depths to further prevent any mixing of the medicaments 20, 22 during or after delivery of the medicaments 20, 22.
Looking again to
Looking now to
Illustratively, the needle 232 permits the first and second medicaments 20, 22 to mix with each other prior to being delivered into the patient. For example, the first medicament 20 may enter the uptake arm 244 of the needle 232 and travel along the transverse arm 248 to the delivery arm 242. The second medicament 22 may similarly enter the uptake arm 246 of the needle 232 and travel along the transverse arm 250 to mix with the first medicament 20 in the delivery arm 242. The needle 232 may be used with delivery devices where the first and second medicaments 20, 22 contained within such delivery devices are compatible with each other and may be mixed prior to delivery into the patient. Of course, with separate basal and bolus delivery mechanisms, there may be instances where only the first medicament 20 or only the second medicament 22 is being delivered through the needle 232.
While the “Y-shaped” needle 232 is disclosed herein for use with compatible medicaments able to be mixed together, it should be understood that other suitable needles may be used which permit the medicaments to mix with each other after leaving the fluid reservoirs within which each is stored. For example, it is to be understood that Y-shapes are intended to encompass T-shapes. Further illustratively, a cover button 252 is shown in
According to one aspect of the present disclosure, a fluid delivery device may include a plurality of drug reservoirs for containing and delivering a plurality of different medicaments. For example, while the fluid delivery devices described above and shown in
According to another aspect of the present disclosure, the delivery devices disclosed herein are relatively compact, portable, and able to be fixed to the user or patient during use and subsequently disposed of when the treatment is finished. Of course, other such non-portable and non-disposable delivery devices are included within the scope of this disclosure as well.
According to still another aspect of the present disclosure, the fluid delivery devices described herein are adapted to deliver two different medicaments 20 and 22. In one embodiment, the first and second medicaments 20, 22 are selected as being adapted for treating two different diseases that may occur in a co-morbid disease state. In another embodiment, the first and second medicaments 20, 22 are selected as being adapted for treating two different symptoms that may be present in a single disease. In another embodiment, the first and second medicaments 20, 22 are selected as being adapted for treating the same disease and/or symptom where such a combination of such two or more medicaments may be contemplated or desirable.
In another embodiment, the first and second medicaments 20, 22 are selected as being adapted for treating a disease state where for example, one of the first or second medicaments 20, 22 causes undesirable or unwanted side effects or other adverse events, and the other of the first and second medicaments 20, 22 mediates, ameliorates, or alleviates those side effects or adverse events.
In another embodiment, the first and second medicaments 20, 22 are selected as being adapted for treating a disease state where the efficacy or performance of one of the first or second medicaments 20, 22 is enhanced or improved by the co-administration of the other of the first or second medicaments 20, 22. Efficacy enhancement may be additive or synergistic, or may correct for or mediate sensitization, desensitization or tolerance that may accompany the use of one of the first or second medicaments 20, 22. It is appreciated that such enhancement or improvement may lead to the lowering of the overall amount of the medicament whose efficacy or performance is enhanced.
It is understood that the devices described herein may allow for the pairing of two medicaments that otherwise could not be delivered in a unitary dosage form by conventional means. For example, certain pairings of medicaments may not be possible in conventional unitary dosage forms due to chemical incompatibility, differential stability requirements, different formulation requirements, and other optimization parameters needed for efficacy. Further, certain pairings of medicaments may not be possible in conventional unitary dosage forms due to the need for flexibility in altering the ratio of the first and second medicaments. It is suggested that conventional dosage forms would require a fixed ratio. Further, certain pairings of medicaments may not be possible in conventional unitary dosage forms due to complicated dosing regimens requiring alternate administration over predetermined time periods. It is to be further understood that though the foregoing describes drug pairings, those aspects apply equally to embodiments of the delivery devices described herein that are configured to deliver three or more medicaments.
In one embodiment, the devices described herein are adapted for delivering medicaments to treat diabetes, including Type I and Type II diabetes, diabetic symptoms, and diabetic conditions.
In one embodiment, the first or second medicament 20, 22 is insulin or an insulin analog, and the other medicament 20, 22 is drug selected to improve the performance, or decrease the side effect profile of the insulin or insulin analog. It is to be understood that the first and second medicaments 20, 22 may each refer to the insulin or analog thereof. For example, as used herein, insulin analogs include pro-insulin, pre-insulin, and insulins that have been modified with various amino acids, such as with insertions, deletions, and substitutions. The devices described herein include various options as to the presence or absence of bolus and/or basal delivery, the relative size of the bolus delivery, the relative rate of the basal delivery, and other features. Accordingly, in some embodiments of the devices, the insulin or insulin analog is the first medicament 20, while in other embodiments, the insulin or insulin analog is the second medicament 22. Accordingly, as used throughout the terms first medicament 20 and second medicament 22 may be interchanged with the identification of the medicament for different configurations and embodiments of the devices described herein.
In another embodiment, both natural and synthetic insulins and insulin analogs may be used as the first or second medicament 20, 22. In one aspect, insulins used are naturally occurring, such as naturally occurring human insulins and analogs thereof, including but not limited to those produced using recombinant methods from other organisms such as bacteria. In another aspect, insulins used are synthetic insulins, or modified insulins including amino acid chain modifications such as insertions, deletions, and exchanges in the insulin sequence. Illustratively, the insulins are Lispro insulin, Aspart insulin, Glargine insulin, Detemir insulin, and the like. Further, insulins include but are not limited to the amino acid insertions, amino acid deletions, and amino acid substitutions of various insulins from human and other sources. It is understood that such modifications may be made on the A or B chains. Illustratively, insulins may be included as medicaments 20, 22 herein, where Asp28 on the B-chain is substituted, such as with Pro28 or Lys28; where Lys29 in the B-chain is substituted with Pro29 or Glu29; where the B-chain is extended, such as with Arg31 or Arg31-Arg32; where Asn 21 on the A-chain is substituted, such as with Gly21; where Asn3 on the B-chain is substituted, such as with Lys3; and similar modifications.
In another aspect, insulins used as medicaments herein are intermediate acting insulins, including but not limited to HUMULIN L, HUMULIN N, NOVOLIN N, NOVOLIN R, and the like. In another aspect, insulins used as medicaments herein are rapid acting insulins, including but not limited to APIDRA, HUMALOG HUMULIN R, NOVOLIN R, NOVOLOG, and the like. In another aspect, insulins used as medicaments herein are long acting insulins, including but not limited to HUMULIN U, LANTUS, and the like. In another aspect, insulins used as medicaments herein are mixtures of various insulins, including but not limited to HUMALOG MIX 75/25, HUMULIN 50/50, HUMULIN 70/30, NOVOLIN 70/30, NOVOLOG MIX 70/30, and the like.
In one variation, both medicaments 20, 22 are insulins. It is appreciated that more varied mixtures of insulins may be delivered to certain patients using configurations where the first medicament 20 is one insulin, and the second medicament 22 is another insulin. It is understood that insulins may be selected to suit the needs of various subpopulations of patients for which readily available premixed insulins are less desirable, or where mixing insulins is not desirable. In another aspect the first insulin is long acting insulins such as HUMULIN U, LANTUS, and the like, and the second insulin is an intermediate or short acting insulin, as described herein. In one configuration, the device is selected such that both the first and second medicaments 20, 22 are primarily or exclusively administered to the patient in a bolus manner rather than a basal manner. In those configuration, it is understood that for example, the long acting insulin may be administered as a once-per-day bolus amount, and the short or intermediate acting insulin is administered in a meal-time ready bolus amount. In one variation it is contemplated that the short or intermediate acting insulin may be administered in a basal manner as well, or in another variation the short or intermediate acting insulin may be administered in a basal manner over a shortened period of time to correspond with meal time.
In an alternate embodiment, the other medicament 20, 22 may be included to increase the efficacy of, improve the performance of, or decrease the side effect profile of the insulin or insulin analog used as a medicament. The mechanisms for this increased insulin efficacy or improved performance may be any, including improving endogenous insulin production, decreasing insulin resistance or insulin insensitivity, improving the utilization of insulin and glucose by peripheral tissues, increasing the uptake of glucose by peripheral tissues, decreasing the amount or slowing the rate of endogenous sugar production from certain organs, including but not limited to the liver, decreasing the amount or slowing the rate of gastrointestinal sugar absorption, and the like.
In one configuration, the other medicament is an incretin, incretin mimetic or incretin analog, such as glucagon-like-peptide (GLP), a GLP-1 analog, exenatide (BYETTA, Amylin, Lilly), Extendin-4, and the like. Incretin mimetics and/or incretin analogs may act analogous to Glucagon-Like Peptide-1 (GLP-1), a naturally occurring peptide which enhances insulin secretion in response to elevated plasma glucose levels, may be included as helper drugs. It is understood that the GLP-1 system increases insulin secretion only in the presence of elevated plasma glucose levels, avoiding inappropriately high insulin levels during fasting. It is appreciated that incretins may enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic actions following their release into the circulation. Incretins may also moderate peak serum glucagon levels during hyperglycemic periods following meals, without interfering with glucagon release in response to hypoglycemia. Incretins may also have beneficial secondary effects of reducing the rate of gastric emptying and decrease food intake, mitigating the potential severity of hyperglycemic events after meals. In one embodiment, the devices described herein include a daily dose of BYETTA in the range from about 5 to about 10 micrograms. In the foregoing configuration, it is appreciated that devices may be selected that include a separate needle for each of the reservoirs containing medicaments 20, 22, such that substantial mixing of the two medicaments does not occur at, or optionally near, the sites of injection.
In another configuration, the other medicament is an amylin peptide, such as pramlintide (SIMLYN, Amylin). It is appreciated that deficiencies in insulin may parallel deficiencies in amylin. Amylin may have a moderating effect on blood glucose absorption from the gut into the blood, slowing and managing meal-derived glucose inflow, controlling pancreatic glucagon secretion, and consequently regulating hepatic glucose production. In the foregoing configuration, it is appreciated that devices may be selected that include a separate needle for each of the reservoirs containing medicaments 20, 22, such that substantial mixing of the two medicaments does not occur at, or optionally near, the sites of injection.
In another configuration, the other medicament is a biguanide or biguanide combination In one illustrative aspect, the biguanide is metformin (GLUCOPHAGE, FORTAMET, RIOMET). In another illustrative aspect, the biguanide is an inhibitor of hepatic glucose production. In another aspect, the biguanide is an inhibitor of gastrointestinal glucose absorption. It is appreciated that biguanides may increase the efficacy of insulin therapy by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and/or increasing peripheral glucose uptake and utilization. In one variation, pharmaceutically acceptable salts of such medicaments are included in the devices described herein.
In another configuration, the other medicament is a glucosidase inhibitor, such as acarbose (PRECOSE, Bayer), and the like. It is appreciated that glucosidase inhibitors may increase the efficacy of insulin therapy by slowing either the pancreatic and/or intestinal hydrolysis of complex carbohydrates to glucose.
In another configuration, the other medicament is a sulfonylurea, such as Amaryl glimepiride (AMARYL, Aventis), glyburide (DIABETA, Aventis), glipizide (GLUCOTROL, Pfizer), and like insulin secretagogues. It is appreciated that sulfonylureas may increase the efficacy of insulin therapy by increasing the amount of endogenous insulin secretion, such as from pancreatic beta cells. In addition, sulfonylureas may increase the efficacy of insulin therapy by increasing the sensitivity of peripheral tissues to insulin.
In another configuration, the other medicament is a meglitinide, such as repaglinide (PRANDIN, Novo Nordisk), nateglidine (STARLIX, Novatis), and like insulin secretagogues. It is appreciated that meglitinides may increase the efficacy of insulin therapy by increasing the amount of endogenous insulin secretion, such as from pancreatic beta cells, by blocking ATP-dependent potassium channels.
In another configuration, the other medicament is an agonist of a peroxisome proliferator activated receptor (PPAR) such as PPARγ. In one embodiment, the PPARγ agonist is a thiazolidinedione (TZD) insulin sensitizer, including but not limited to pioglitazone (ACTOS, Takeda), AVANDAMET (GlaxoSmithKline), rosiglitazone maleate (AVANDIA, GlaxoSmithKline), phenformin, buformin, and the like. It is appreciated that TZD insulin sensitizers and other PPARγ agonists may increase the efficacy of insulin therapy by decreasing insulin resistance or insensitivity in peripheral tissues and in the liver, resulting in increased insulin dependent glucose disposal and decreased hepatic glucose output. It is appreciated that compounds that also lack PPARα binding action may be advantageously included in the devices described herein.
In another configuration, mixtures of such other medicaments are contemplated. Illustratively, the mixture may be of a TZD insulin sensitizer or PPARγ agonist and a biguanide, such as metformin mixed with rosiglitazone maleate (AVANDAMET, GlaxoSmithKline), and like mixtures. It is appreciated that other drugs that reduce hepatic gluconeogenesis may be included alone or in combination with TZDs. It is also appreciated that other drugs that decrease intestinal absorption of glucose may be included alone or in combination with TZDs. It is also appreciated that other drugs that improves insulin sensitivity by increasing peripheral glucose uptake and utilization may be included alone or in combination with TZDs. In addition, the mixture may be of an incretin mimetic or incretin analog and a biguanide or sulfonyl urea, such as exenatide mixed with metformin or glimepiride, and like mixtures. In addition, the mixture may be of a biguanide and a sulfonylurea, such as metformin mixed with glipizide (METAGLIP, Bristol Meyers Squibb), and like mixtures.
In another configuration, the other medicament is a saccharide, such as a glucagon or an analog thereof. It is appreciated that during insulin administration with the devices described herein, it may be desirable or necessary to moderate and/or lessen the impact of insulin administration that may result in hypoglycemia or a hypoglycemic condition. It is further appreciated that the administration of such a saccharide may be controlled by the basal functions of the devices described herein, or alternatively by the bolus functions of the devices described herein. For example, in one illustrative embodiment, upon the onset of hypoglycemia or a hypoglycemic condition, the patient being treated may initiate a bolus administration of the saccharide. It is understood that the onset of hypoglycemia or a hypoglycemic condition may be determined using any conventional method of monitoring blood-glucose levels, including but not limited to blood-glucose strips, and the like. In one variation, the onset of hypoglycemia or a hypoglycemic condition may be determined by the patient through training, and/or experience in recognizing certain symptoms indicating such hypoglycemia or a hypoglycemic condition. It is further understood that in other configurations, it is less desirable to have any sustained levels of glucagon administration, and therefore one variation of this embodiment would include bolus delivery of the saccharide as the primary or exclusive route of administration.
In another configuration, the other medicament is insulin-like growth factor (IGF) 1 or 2, or an analog or derivative thereof. It is appreciated that IGF-1 and/or IGF-2 may be administered with insulin, or analogs thereof, to decrease hypoglycemia and/or hypoglycemic conditions that may be caused by insulin administration alone. IGF-1 and IGF-2 bind to insulin receptors, but with much lower affinity than does insulin, such as at about 10-fold or even 100-fold less affinity than insulin. Without being bound by theory, it is suggested co-administration of IGF-1 or IGF-2, or an analog or derivative thereof, may decrease insulin sensitivity and therefore may decrease the potential for the onset of hypoglycemia and/or hypoglycemic conditions caused by insulin administration. It is understood that IGF-1 and IGF-2 may be rapidly bound to binding proteins upon administration. Accordingly, ligand conjugates of IGF-1 and IGF-2, and their analogs, are also contemplated herein. Such ligand conjugates may increase the overall bioavailability of the IGF-1 and IGF-2, or analog thereof that is administered as described herein.
In another configuration, the other medicament is C-peptide, or an analog thereof. It is understood that in endogenous insulin production and metabolism, pro-insulin is made in the β-cells and once release it is cleaved by peptidases to release the C-peptide fragment. Finally, carboxypeptidase E produces the mature insulin by truncating the terminus of the B-chain. It is appreciated that C-peptide may be co-administered with the insulin, or any analog or derivative thereof, as the second medicament. Without being bound be theory, it is suggested that C-peptide is useful in regulation of glucose metabolism and also in other biologically important processes, and therefore, the complete or near complete replacement of endogenous insulin with exogenous sources may lead to an undesirable level of C-peptide. For example, neuropathy is a co-morbid pathology that may accompany diabetes or other diabetic conditions or condition of glucose dysregulation. Thus, it is suggested that C-peptide administration may treat neuropathy, decrease the progression of neuropathy, or delay or halt the onset of neuropathy. It is appreciated that the devices described herein may lead to better patient compliance than conventional methods, including conventional methods that include administering C-peptide by injection.
In one aspect, the C-peptide, or analog or derivative thereof, is administered to the patient at a ratio of about 1:1 on a molar basis compared to the insulin, thus mirroring the endogenous condition in healthy patients. In another aspect, the C-peptide, or analog or derivative thereof, is administered to the patient at a ratio of less than 1:1 on a molar basis compared to the insulin. In this latter embodiment, it is understood that levels of C-peptide may not need to be maintained as high as those of insulin to treat diabetes and associated conditions. In addition, it is understood that C-peptide administration may lead to a plateau effect, and accordingly, patient needs for C-peptide may decrease over time. Thus, in this alternate aspect, the C-peptide, or analog or derivative thereof, is administered to the patient at a ratio of about 4:5, about 3:4, about 2:3, or about 1:2 on a molar basis compared to the insulin.
In addition, it is appreciated that though the foregoing embodiment where the second medicament is C-peptide, or an analog or derivative thereof, may be administered using any of the devices described herein, in one variation, devices are selected that include a single needle, whereby both medicaments 20, 22 mix prior to administration. In another variation, devices are selected that include two or more needles, where at least two of such needles are located proximally to the other, thus allowing both medicaments 20, 22 to mix immediately or soon after administration at the site of entry into the patient.
In another configuration, the first and second medicaments 20, 22 are both anti-infective compounds. In one aspect, the anti-infective compounds are antibacterial agents, such as penicillins and related compounds, including carbacephems, carbapenems, cephalosporins, and the like, monobactams, polypeptides, aminoglycosides, glycopeptides, vancomycins, macrolide antibiotics including erythromycins, quinolones, sulfonamides, tetracyclines, and the like.
Illustrative aminoglycosides that may be included in the devices described herein include, but at not limited to, amikacin, gentamicin, kanamycin, neomycin, netilmicin, streptomycin, tobramycin, and the like. Illustrative carbacephems include loracarbef and the like. Illustrative carbapenems include ertapenem, imipenem, cilastatin, meropenem, and the like. Illustrative cephalosporins include first, second, third, and fourth generation cephalosporins, such as cefadroxil, cefazolin, cephalexin, cefaclor, cefamandole, cefoxitin, cefprozil, cefuroxime, cefixime, cefdinir, cefditoren, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, cefepime, and the like.
Illustrative macrolides that may be included in the devices described herein include, but at not limited to, azithromycin, clarithromycin, dirithromycin, erythromycin, roxithromyucin, troleandomycin, and the like. Illustrative glycopeptides that may be included in the devices described herein include teicoplanin, vancomycin, and the like. Illustrative penicillins include amoxicillin, ampicillin, azlocillin, cabenicillin, cloxacillin, and the like, and monobactams include aztreonam, and the like. Illustrative polypeptides include bacitracin, colistin, polymyxin B, and the like.
Illustrative quinolones includes ciprofloxacin, enoxacin, gatifloxacin, levofloxacin moxifloxacin, and the like. Illustrative sulfonamides include mafenide, sulfacetamide, sulfamethizole, sulfasalazine, sulfisoxazole, trimethoprim, BACTRIM, and the like. Illustrative tetracyclines include demeclocycline, doxycycline, minocycline, oxytetracycline, tetracycline, and the like. Still other illustrative antibiotics that may be included in the devices described herein include, but at not limited to, arsphenamine, chloramphenicol, floramphenicol, clindamycin, ethambutol, fosfomycin, furzolidone, isoniazid, linezolid, metronidazole, nitrofurantoin, rifampin, spectinomycin, telithromycin, and the like.
In another embodiment, the first and second medicaments 20, 22 are agonists or antagonists of neurotransmitter receptors. In one illustrative aspect, the first medicament is dopamine or a dopamine receptor agonist, and the second medicament is a dopamine receptor antagonist. Illustrative dopamine receptor agonists and antagonists are described in PCT international application serial No. PCT/US2004/043145, the disclosure of which is incorporated herein in its entirety by reference. In one aspect, the dopamine agonist is selective for the dopamine D1 receptor. In another aspect, the dopamine antagonist is selective for the dopamine D2 receptor. It is appreciated that the co-administration of a dopamine D2 receptor antagonist may enhance or improve the efficacy or overall benefit of the dopamine receptor agonist, including dopamine D1 receptor agonists. It is also appreciated that the co-administration of a dopamine D2 receptor antagonist may decrease, ameliorate, or alleviate side effects associated with the dopamine receptor agonist, including dopamine D1 receptor agonists.
Illustrative dopamine D2 receptor antagonists that may be included in the devices described herein include, but at not limited to, compounds of the formulae:
and pharmaceutically acceptable salts thereof, wherein R is hydrogen or C1-C4 alkyl; R1 is hydrogen, acyl, such as C1-C4 alkanoyl, benzoyl, pivaloyl, and the like, or an optionally substituted phenyl or phenoxy protecting group, such as a prodrug and the like; X is hydrogen, fluoro, chloro, bromo, iodo or a group of the formula —OR8 wherein R8 is hydrogen, C1-C4 alkyl, acyl, such as C1-C4 alkanoyl, benzoyl, pivaloyl, and the like, or an optionally substituted phenyl or phenoxy protecting group, provided that when X is a group of the formula —OR8, the groups R1 and R8 can optionally be taken together to form a —CH2— or —(CH2)2— group, thus representing a methylenedioxy or ethylenedioxy functional group; RA, R2, R3, R4, R5, R6, and R7 are each independently selected from hydrogen, C1-C4 alkyl, phenyl, fluoro, chloro, bromo, iodo, and a group —OR9 wherein R9 is hydrogen, acyl, such as C1-C4 alkanoyl, benzoyl, pivaloyl, and the like, or an optionally substituted phenyl or phenoxy protecting group; and RB is selected from hydrogen, C1-C4 alkyl, phenyl, fluoro, chloro, bromo, iodo, a group —OR9 wherein R9 is hydrogen, acyl, such as C1-C4 alkanoyl, benzoyl, pivaloyl, and the like, —OR1 and X, as defined above, and optionally substituted phenyl or phenoxy protecting groups, providing that at least one of RB is —OR1.
Illustrative dopamine D2 receptor antagonists that may be included in the devices described herein include, but at not limited to, antipsychotic agents, illustratively selected from the typical and atypical families of antipsychotic agents. It is appreciated that atypical antipsychotics may generally be associated with less acute extrapyramidal symptoms, especially dystonias, and less frequent and smaller increases in serum prolactin concentrations associated with therapy. In one aspect, the typical antipsychotic agents include phenothiazines and non-phenothiazines such as loxapine, molindone, and the like. In another aspect, the atypical antipsychotic agents include the clozapine-like agents, and others, including aripiprazole, risperidone (3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino]ethyl]-2-methyl-6,7,8,9-tetrahydro-4H-pyrido-[1,2-a]pyrimidin-4-one), amisulpiride, sertindole (1-[2[4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]-1-piperidinyl]ethyl]imidazolidin-2-one), and the like. Phenothiazines include, but are not limited to chlorpromazine, fluphenazine, mesoridazine, perphenazine, prochlorperazine, thioridazine, and trifluoperazine. Non-phenothiazines include, but are not limited to haloperidol, pimozide, and thiothixene. Other clozapine-like agents include, but are not limited to olanzapine (2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine), clozapine (8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine), quetiapine (5-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol), ziprasidone (5-[2-[4-(1,2-benzoisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one), and the like. It is appreciated that other typical and atypical antipsychotic agents may be used as the dopamine receptor antagonist described herein. It is also appreciated that various combinations of typical and atypical antipsychotic agents may be used.
The devices described herein may be configured to deliver daily dosage amounts of the various first and second medicaments 20, 22 at bioequivalency levels comparable to conventional drug formulations. Illustratively, metformin may be delivered at rates that correlate to the conventional oral dosage of 500, 850, 1,000, or 2,000 mg/day. It is to be understood that the amount delivered by the parenteral routes described herein for the various devices will often be substantially lower than the equivalent oral dosage form. For example, metformin may be delivered in a pulsatile or bolus delivery profile at a rate that corresponds to values that do not exceed the peak plasma concentration (Cmax) observed for the oral dosage form, such in the range from about 0.5 to about 4 μg/mL. Alternatively, metformin may be delivered in a sustained or basal delivery profile at a rates lower than the Cmax, and corresponding to the average value under the area under curve (AUC), such as in the range from about 4 to about 10 μg·h/mL. These and other values for metformin, as well as for other first and second medicaments 20, 22 described herein are found in and/or routinely derived from values presented for the conventional dosage forms of such medicaments in Physicians' Desk Reference, Thompson PDR, Montvale N.J. (59th edition, 2005), the disclosure of which is incorporated herein by reference.
It is suggested that the devices described herein may be particularly appropriate for basal delivery, or alternatively bolus delivery at more frequent and lower doses, of medicaments that are delivered conventionally once or twice per day due to formulation issues, convenience, or poor expected patient compliance. Accordingly, the devices described herein may be configured to deliver pharmacokinetic (PK) profiles of medicaments that are not possible with conventional formulations. For example, the peak-valley PK profile generally accompanying once a day dosing may be converted to a lower level sustained release PK profile, or a lower peak-higher valley more frequent pulsatile PK profile.
There are a plurality of advantages of the present disclosure arising from the various features of the apparatus and methods described herein. It will be noted that alternative embodiments of the apparatus and methods of the present disclosure may not include all of the features described yet still benefit from at least some of the advantages of such features. Those of ordinary skill in the art may readily devise their own implementations of an apparatus and method that incorporate one or more of the features of the present disclosure and fall within the spirit and scope of the present disclosure.
This application is a continuation of U.S. application Ser. No. 14/341,879 filed Jul. 28, 2014, which is a continuation of U.S. application Ser. No. 13/719,481 filed on Dec. 19, 2012, now U.S. Pat. No. 8,821,443, which is a continuation of U.S. application Ser. No. 13/013,379, now U.S. Pat. No. 8,361,053, filed Jan. 25, 2011 which is a continuation of U.S. application Ser. No. 12/295,173, now U.S. Pat. No. 7,914,499, filed Mar. 28, 2007, which is a U.S. National Stage Entry of International Application No. PCT/US2007/065363, filed Mar. 28, 2007, which claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application Ser. No. 60/787,616, filed Mar. 30, 2006, the disclosures of which are hereby incorporated by reference herein in their entirety. In addition, cross-reference is made to U.S. Pat. No. 6,939,324 titled FLUID DELIVERY AND MEASUREMENT SYSTEMS AND METHODS; U.S. Patent Application Publication No. US 2005/0119618 titled HYDRAULICALLY ACTUATED PUMP FOR LONG DURATION MEDICAMENT ADMINISTRATION; and U.S. application Ser. No. 11/219,944 titled FLUID DELIVERY AND MEASUREMENT SYSTEMS AND METHODS, the disclosure of each of which is hereby incorporated by reference herein.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2828743 | Ashkenaz et al. | Apr 1858 | A |
| 2605765 | Kollsman | Aug 1952 | A |
| 2702547 | Glass | Feb 1955 | A |
| 3055362 | Uytenbogaart | Sep 1962 | A |
| 3187749 | Samoff | Jun 1965 | A |
| 3731681 | Blackshear et al. | May 1973 | A |
| 3886938 | Szabo | Jun 1975 | A |
| 3963151 | North, Jr. | Jun 1976 | A |
| 4042153 | Callahan et al. | Aug 1977 | A |
| 4065230 | Gezari | Dec 1977 | A |
| 4085749 | Chambron | Apr 1978 | A |
| 4150672 | Whitney et al. | Apr 1979 | A |
| 4190048 | Sampson | Feb 1980 | A |
| 4193397 | Tucker et al. | Mar 1980 | A |
| 4202333 | Thill et al. | May 1980 | A |
| 4209014 | Sefton | Jun 1980 | A |
| 4258711 | Tucker et al. | Mar 1981 | A |
| 4263323 | Carlsson et al. | Apr 1981 | A |
| 4265241 | Portner et al. | May 1981 | A |
| 4267836 | Whitney et al. | May 1981 | A |
| 4298000 | Thill et al. | Nov 1981 | A |
| 4313439 | Babb et al. | Feb 1982 | A |
| 4340048 | Eckenhoff | Jul 1982 | A |
| 4351335 | Whitney et al. | Sep 1982 | A |
| 4360019 | Portner et al. | Nov 1982 | A |
| 4398908 | Siposs | Aug 1983 | A |
| 4411651 | Schulman | Oct 1983 | A |
| 4430079 | Thill et al. | Feb 1984 | A |
| 4431426 | Groshong et al. | Feb 1984 | A |
| 4437859 | Whitehouse et al. | Mar 1984 | A |
| 4443218 | Whitehouse et al. | Mar 1984 | A |
| 4496343 | Prosl | Jan 1985 | A |
| 4505701 | Novato | Mar 1985 | A |
| 4525165 | Fischell | Jun 1985 | A |
| 4529401 | Leslie et al. | Jul 1985 | A |
| 4548607 | Harris | Oct 1985 | A |
| 4552561 | Eckenhoff et al. | Nov 1985 | A |
| 4559038 | Berg et al. | Dec 1985 | A |
| 4561856 | Cochran | Dec 1985 | A |
| 4565542 | Berg | Jan 1986 | A |
| 4568335 | Updike et al. | Feb 1986 | A |
| 4583973 | Humphrey et al. | Apr 1986 | A |
| 4596575 | Rosenberg et al. | Jun 1986 | A |
| 4601707 | Albisser et al. | Jul 1986 | A |
| 4627839 | Young | Dec 1986 | A |
| 4648872 | Kamen | Mar 1987 | A |
| 4650469 | Berg et al. | Mar 1987 | A |
| 4685902 | Edwards et al. | Aug 1987 | A |
| 4699615 | Fischell et al. | Oct 1987 | A |
| 4715852 | Reinicke et al. | Dec 1987 | A |
| 4718893 | Dorman et al. | Jan 1988 | A |
| 4723947 | Konopka | Feb 1988 | A |
| 4731058 | Doan | Mar 1988 | A |
| 4734092 | Millerd | Mar 1988 | A |
| 4741736 | Brown | May 1988 | A |
| 4744786 | Hooven | May 1988 | A |
| 4747824 | Spinello | May 1988 | A |
| 4749109 | Kamen | Jun 1988 | A |
| 4755172 | Baldwin | Jul 1988 | A |
| 4772263 | Dorman et al. | Sep 1988 | A |
| 4772273 | Alchas | Sep 1988 | A |
| 4781688 | Thoma et al. | Nov 1988 | A |
| 4784576 | Bloom et al. | Nov 1988 | A |
| 4784577 | Ritson et al. | Nov 1988 | A |
| 4790829 | Bowden et al. | Dec 1988 | A |
| 4808161 | Kamen | Feb 1989 | A |
| 4808167 | Mann et al. | Feb 1989 | A |
| 4813951 | Cannon et al. | Mar 1989 | A |
| 4816019 | Kamen | Mar 1989 | A |
| 4818186 | Pastrone et al. | Apr 1989 | A |
| 4822339 | Tran | Apr 1989 | A |
| 4826482 | Kamen | May 1989 | A |
| 4834704 | Reinicke | May 1989 | A |
| 4838857 | Strowe et al. | Jun 1989 | A |
| 4842584 | Pastrone | Jun 1989 | A |
| 4846806 | Wigness et al. | Jul 1989 | A |
| 4856340 | Garrison | Aug 1989 | A |
| 4861341 | Woodburn | Aug 1989 | A |
| 4874386 | O'Boyle | Oct 1989 | A |
| 4886499 | Cirelli et al. | Dec 1989 | A |
| 4894054 | Miskinyar | Jan 1990 | A |
| 4900305 | Smith et al. | Feb 1990 | A |
| 4902278 | Maget et al. | Feb 1990 | A |
| 4919134 | Streeter | Apr 1990 | A |
| 4925444 | Orkin et al. | May 1990 | A |
| 4927411 | Pastrone et al. | May 1990 | A |
| 4931050 | Idriss | Jun 1990 | A |
| 4952210 | Alchas | Aug 1990 | A |
| 4971900 | Ahnell et al. | Nov 1990 | A |
| 4976162 | Kamen | Dec 1990 | A |
| 4976696 | Sanderson et al. | Dec 1990 | A |
| 4998926 | Alchas | Mar 1991 | A |
| 5000994 | Romberg et al. | Mar 1991 | A |
| 5009641 | Gorton | Apr 1991 | A |
| 5024664 | Mitchell | Jun 1991 | A |
| 5037396 | Streeter | Aug 1991 | A |
| 5039279 | Natwick et al. | Aug 1991 | A |
| 5041094 | Perego et al. | Aug 1991 | A |
| 5045064 | Idriss | Sep 1991 | A |
| 5053031 | Borsanyi | Oct 1991 | A |
| 5055001 | Natwick et al. | Oct 1991 | A |
| 5059174 | Vaillancourt | Oct 1991 | A |
| 5062774 | Kramer et al. | Nov 1991 | A |
| 5088515 | Kamen | Feb 1992 | A |
| 5090963 | Gross et al. | Feb 1992 | A |
| 5098262 | Wecker et al. | Mar 1992 | A |
| 5100380 | Epstein et al. | Mar 1992 | A |
| 5106374 | Apperson et al. | Apr 1992 | A |
| 5108367 | Epstein et al. | Apr 1992 | A |
| 5135498 | Kam et al. | Aug 1992 | A |
| 5135500 | Zdeb | Aug 1992 | A |
| 5144515 | Frauhauf et al. | Sep 1992 | A |
| 5158437 | Natwick et al. | Oct 1992 | A |
| 5165869 | Reynolds | Nov 1992 | A |
| 5167631 | Thompson et al. | Dec 1992 | A |
| 5169390 | Athayde et al. | Dec 1992 | A |
| 5176502 | Sanderson et al. | Jan 1993 | A |
| 5176641 | Idriss | Jan 1993 | A |
| 5176644 | Srisathapat et al. | Jan 1993 | A |
| 5178182 | Kamen | Jan 1993 | A |
| 5178609 | Ishikawa | Jan 1993 | A |
| 5180287 | Natwick et al. | Jan 1993 | A |
| 5181910 | Scanlon | Jan 1993 | A |
| 5188603 | Vaillancourt | Feb 1993 | A |
| 5193990 | Kamen et al. | Mar 1993 | A |
| 5197322 | Indravudh | Mar 1993 | A |
| 5207642 | Orkin et al. | May 1993 | A |
| 5207666 | Idriss et al. | May 1993 | A |
| 5211201 | Kamen et al. | May 1993 | A |
| 5217442 | Davis | Jun 1993 | A |
| 5219279 | Natwick et al. | Jun 1993 | A |
| 5219428 | Stern | Jun 1993 | A |
| 5222946 | Kamen | Jun 1993 | A |
| 5232449 | Stern et al. | Aug 1993 | A |
| 5242408 | Jhuboo et al. | Sep 1993 | A |
| 5248300 | Bryant et al. | Sep 1993 | A |
| 5250649 | Onwumere et al. | Oct 1993 | A |
| 5254096 | Rondelet et al. | Oct 1993 | A |
| 5257971 | Lord et al. | Nov 1993 | A |
| 5257987 | Athayde et al. | Nov 1993 | A |
| 5259732 | Stern | Nov 1993 | A |
| 5261884 | Stern et al. | Nov 1993 | A |
| 5281210 | Burke et al. | Jan 1994 | A |
| 5290240 | Horres, Jr. | Mar 1994 | A |
| 5295966 | Stern et al. | Mar 1994 | A |
| 5295967 | Rondelet et al. | Mar 1994 | A |
| 5298023 | Haber | Mar 1994 | A |
| 5300041 | Harber et al. | Apr 1994 | A |
| 5304126 | Epstein et al. | Apr 1994 | A |
| 5306257 | Zdeb | Apr 1994 | A |
| 5312364 | Jacobs et al. | May 1994 | A |
| 5318540 | Athayde et al. | Jun 1994 | A |
| 5319979 | Abrahamson | Jun 1994 | A |
| 5320600 | Lambert | Jun 1994 | A |
| 5322422 | Natwick et al. | Jun 1994 | A |
| 5328459 | Laghi | Jul 1994 | A |
| 5338157 | Blomquist | Aug 1994 | A |
| 5338312 | Montgomery | Aug 1994 | A |
| 5349852 | Kamen et al. | Sep 1994 | A |
| 5350357 | Kamen et al. | Sep 1994 | A |
| 5356379 | Vaillancourt | Oct 1994 | A |
| 5364242 | Olsen | Nov 1994 | A |
| 5368562 | Blomquist et al. | Nov 1994 | A |
| 5368571 | Horres, Jr. | Nov 1994 | A |
| 5370622 | Livingston et al. | Dec 1994 | A |
| 5376070 | Purvis et al. | Dec 1994 | A |
| 5380334 | Torrie et al. | Jan 1995 | A |
| 5389078 | Zalesky et al. | Feb 1995 | A |
| 2703084 | Tomlinson | Mar 1995 | A |
| 5396925 | Poli | Mar 1995 | A |
| 5399166 | Laing | Mar 1995 | A |
| 5399823 | McCusker | Mar 1995 | A |
| 5405614 | D'Angelo et al. | Apr 1995 | A |
| 5421823 | Kamen et al. | Jun 1995 | A |
| 5431626 | Bryant et al. | Jul 1995 | A |
| 5431634 | Brown | Jul 1995 | A |
| 5433710 | Van Antwerp et al. | Jul 1995 | A |
| 5438510 | Bryant | Aug 1995 | A |
| 5445621 | Poll et al. | Aug 1995 | A |
| 5447286 | Kamen et al. | Sep 1995 | A |
| 5453099 | Lee et al. | Sep 1995 | A |
| 5456909 | Marsh, Jr. et al. | Oct 1995 | A |
| 5456940 | Funderburk | Oct 1995 | A |
| 5460618 | Harreld | Oct 1995 | A |
| 5462525 | Srisathapat et al. | Oct 1995 | A |
| 5465392 | Epstein et al. | Nov 1995 | A |
| 5466218 | Srisathapat et al. | Nov 1995 | A |
| 5472317 | Field et al. | Dec 1995 | A |
| 5474683 | Bryant et al. | Dec 1995 | A |
| 5480386 | Brohy et al. | Jan 1996 | A |
| 5485408 | Blomquist | Jan 1996 | A |
| 5487737 | Meyer et al. | Jan 1996 | A |
| 5492534 | Athayde et al. | Feb 1996 | A |
| 5505704 | Pawelka et al. | Apr 1996 | A |
| 5505706 | Maus et al. | Apr 1996 | A |
| 5505709 | Funderburk et al. | Apr 1996 | A |
| 5505713 | Van Antwerp | Apr 1996 | A |
| 5507277 | Rubsamen et al. | Apr 1996 | A |
| 5514103 | Srisathapat | May 1996 | A |
| 5515713 | Saugues et al. | May 1996 | A |
| 5526844 | Karmen et al. | Jun 1996 | A |
| 5527288 | Gross et al. | Jun 1996 | A |
| 5527307 | Srisathapat | Jun 1996 | A |
| 5529463 | Layer et al. | Jun 1996 | A |
| 5531697 | Olsen et al. | Jul 1996 | A |
| 5531698 | Olsen | Jul 1996 | A |
| 5533389 | Kamen et al. | Jul 1996 | A |
| 5533994 | Meyer et al. | Jul 1996 | A |
| 5538399 | Johnson | Jul 1996 | A |
| 5538511 | Van Antwerp | Jul 1996 | A |
| 5540561 | Johnson | Jul 1996 | A |
| 5541562 | Fletcher et al. | Jul 1996 | A |
| 5544519 | Hammarberg et al. | Aug 1996 | A |
| 5545152 | Funderburk et al. | Aug 1996 | A |
| 5564915 | Johnson | Oct 1996 | A |
| 5567119 | Johnson | Oct 1996 | A |
| 5567136 | Johnson | Oct 1996 | A |
| 5569186 | Lord et al. | Oct 1996 | A |
| 5570716 | Kamen et al. | Nov 1996 | A |
| 5574008 | Johnson et al. | Nov 1996 | A |
| 5575310 | Kamen et al. | Nov 1996 | A |
| 5575770 | Melsky et al. | Nov 1996 | A |
| 5578002 | Slettenmark et al. | Nov 1996 | A |
| 5578005 | Scancoff et al. | Nov 1996 | A |
| 5578012 | Kamen et al. | Nov 1996 | A |
| 5582591 | Cheikh et al. | Dec 1996 | A |
| 5584813 | Livingston et al. | Dec 1996 | A |
| 5602171 | Tang et al. | Feb 1997 | A |
| 5607418 | Arzbaecher | Mar 1997 | A |
| 5614642 | Tang | Mar 1997 | A |
| 5616123 | Cheikh et al. | Apr 1997 | A |
| 5628908 | Kamen et al. | May 1997 | A |
| 5634896 | Bryant et al. | Jun 1997 | A |
| 5635387 | Fei et al. | Jun 1997 | A |
| 5637095 | Nason et al. | Jun 1997 | A |
| 5637099 | Durdin et al. | Jun 1997 | A |
| 5641892 | Larkins et al. | Jun 1997 | A |
| 5647853 | Feldmann et al. | Jul 1997 | A |
| 5647854 | Olsen et al. | Jul 1997 | A |
| 5655534 | Ilmoniemi | Aug 1997 | A |
| 5655897 | Neftel et al. | Aug 1997 | A |
| 5656032 | Kriesel et al. | Aug 1997 | A |
| 5658250 | Blomquist et al. | Aug 1997 | A |
| 5658252 | Johnson | Aug 1997 | A |
| 5660846 | Cheikh et al. | Aug 1997 | A |
| 5665065 | Colman et al. | Sep 1997 | A |
| 5665070 | McPhee | Sep 1997 | A |
| 5669877 | Blomquist | Sep 1997 | A |
| 5672167 | Athayde et al. | Sep 1997 | A |
| 5694919 | Rubsamen et al. | Dec 1997 | A |
| 5695473 | Olsen | Dec 1997 | A |
| 5700244 | Kriesel | Dec 1997 | A |
| 5700904 | Baker et al. | Dec 1997 | A |
| 5702372 | Nelson | Dec 1997 | A |
| 5707361 | Slettenmark et al. | Jan 1998 | A |
| 5713865 | Manning et al. | Feb 1998 | A |
| 5716343 | Kriesel et al. | Feb 1998 | A |
| 5718568 | Neftel et al. | Feb 1998 | A |
| 5722397 | Eppstein | Mar 1998 | A |
| 5722956 | Sims et al. | Mar 1998 | A |
| 5735263 | Rubsamen et al. | Apr 1998 | A |
| 5738658 | Maus et al. | Apr 1998 | A |
| 5741125 | Neftel et al. | Apr 1998 | A |
| 5749835 | Glantz | May 1998 | A |
| 5755683 | Houle et al. | May 1998 | A |
| 5764159 | Neftel et al. | Jun 1998 | A |
| 5772409 | Johnson | Jun 1998 | A |
| 5777060 | Van Antwerp | Jul 1998 | A |
| 5782798 | Rise | Jul 1998 | A |
| 5785681 | Indravudh | Jul 1998 | A |
| 5785688 | Joshi et al. | Jul 1998 | A |
| 5788671 | Johnson | Aug 1998 | A |
| 5788673 | Young et al. | Aug 1998 | A |
| 5788678 | Van Antwerp | Aug 1998 | A |
| 5792123 | Ensminger | Aug 1998 | A |
| 5800420 | Gross et al. | Sep 1998 | A |
| 5800421 | Lemelson | Sep 1998 | A |
| 5807315 | Van Antwerp et al. | Sep 1998 | A |
| 5807375 | Gross et al. | Sep 1998 | A |
| 5810015 | Flaherty | Sep 1998 | A |
| 5810771 | Blomquist | Sep 1998 | A |
| 5820622 | Gross et al. | Oct 1998 | A |
| 5823746 | Johnson | Oct 1998 | A |
| 5827262 | Neftel et al. | Oct 1998 | A |
| 5837234 | Gentile et al. | Nov 1998 | A |
| 5837276 | Cheikh et al. | Nov 1998 | A |
| 5837680 | Moses et al. | Nov 1998 | A |
| 5843023 | Cecchi | Dec 1998 | A |
| 5848990 | Cirelli et al. | Dec 1998 | A |
| 5851197 | Marano et al. | Dec 1998 | A |
| 5858001 | Tsals et al. | Jan 1999 | A |
| 5858969 | Marsh, Jr. et al. | Jan 1999 | A |
| 5868711 | Kramer et al. | Feb 1999 | A |
| 5873857 | Knesel | Feb 1999 | A |
| 5876370 | Blomquist | Mar 1999 | A |
| 5879143 | Cote et al. | Mar 1999 | A |
| 5882494 | Van Antwerp | Mar 1999 | A |
| 5891086 | Weston | Apr 1999 | A |
| 5906592 | Kriesel et al. | May 1999 | A |
| 5921962 | Kriesel et al. | Jul 1999 | A |
| 5928196 | Johnson et al. | Jul 1999 | A |
| 5935099 | Peterson et al. | Aug 1999 | A |
| 5935105 | Manning et al. | Aug 1999 | A |
| 5935106 | Olsen | Aug 1999 | A |
| 5935598 | Sage et al. | Aug 1999 | A |
| 5944695 | Johnson et al. | Aug 1999 | A |
| 5951521 | Mastrototaro et al. | Sep 1999 | A |
| 5952347 | Arison et al. | Sep 1999 | A |
| 5954485 | Johnson et al. | Sep 1999 | A |
| 5954695 | Sims et al. | Sep 1999 | A |
| 5957890 | Mann et al. | Sep 1999 | A |
| 5957895 | Sage et al. | Sep 1999 | A |
| 5960797 | Kramer et al. | Oct 1999 | A |
| 5961499 | Bonutti et al. | Oct 1999 | A |
| 5968014 | Neftel et al. | Oct 1999 | A |
| 5976109 | Heruth | Nov 1999 | A |
| 5989423 | Kamen et al. | Nov 1999 | A |
| 5995860 | Sun et al. | Nov 1999 | A |
| 6002954 | Van Antwerp et al. | Dec 1999 | A |
| 6006753 | Efendic | Dec 1999 | A |
| 6007555 | Devine | Dec 1999 | A |
| 6011984 | Van Antwerp et al. | Jan 2000 | A |
| 6012034 | Hamparian et al. | Jan 2000 | A |
| 6013057 | Danby et al. | Jan 2000 | A |
| 6017318 | Gauthier et al. | Jan 2000 | A |
| 6022316 | Eppstein et al. | Feb 2000 | A |
| 6024539 | Blomquist | Feb 2000 | A |
| 6025331 | Moses et al. | Feb 2000 | A |
| 6030399 | Ignotz et al. | Feb 2000 | A |
| 6040194 | Chick et al. | Mar 2000 | A |
| 6041801 | Gray et al. | Mar 2000 | A |
| 6043273 | Duhaylongsod | Mar 2000 | A |
| 6045734 | Luther et al. | Apr 2000 | A |
| 6048328 | Haller et al. | Apr 2000 | A |
| 6049727 | Crothall | Apr 2000 | A |
| 6051557 | Drucker | Apr 2000 | A |
| 6053893 | Bucher et al. | Apr 2000 | A |
| 6056718 | Funderburk et al. | May 2000 | A |
| 6056734 | Jacobsen et al. | May 2000 | A |
| 6057131 | Marsh, Jr. et al. | May 2000 | A |
| 6065941 | Gray et al. | May 2000 | A |
| 6068613 | Kriesel et al. | May 2000 | A |
| 6079753 | Faust et al. | May 2000 | A |
| 6070761 | Bloom et al. | Jun 2000 | A |
| 6074369 | Sage et al. | Jun 2000 | A |
| 6077055 | Vilks | Jun 2000 | A |
| 6077246 | Kullas et al. | Jun 2000 | A |
| 6077248 | Zumschlinge et al. | Jun 2000 | A |
| 6077259 | Caizza et al. | Jun 2000 | A |
| 6083201 | Skinkle | Jul 2000 | A |
| 6085574 | Neftel et al. | Jul 2000 | A |
| 6087394 | Duhaylongsod | Jul 2000 | A |
| 6092249 | Kamen et al. | Jul 2000 | A |
| 6093167 | Houben et al. | Jul 2000 | A |
| 6093172 | Funderburk et al. | Jul 2000 | A |
| 6110152 | Kovelman | Aug 2000 | A |
| 6110427 | Uffenheimer | Aug 2000 | A |
| 6110721 | Gibbs et al. | Aug 2000 | A |
| 6112111 | Glantz | Aug 2000 | A |
| RE36871 | Epstein et al. | Sep 2000 | E |
| 6120460 | Abreu | Sep 2000 | A |
| 6121320 | Doukas | Sep 2000 | A |
| 6122536 | Sun et al. | Sep 2000 | A |
| 6123668 | Abreu | Sep 2000 | A |
| 6123685 | Reynolds | Sep 2000 | A |
| 6123686 | Olsen et al. | Sep 2000 | A |
| 6126642 | Kriesel et al. | Oct 2000 | A |
| 6127410 | Duhaylongsod | Oct 2000 | A |
| 6135978 | Houben et al. | Oct 2000 | A |
| D434142 | Cheney, II et al. | Nov 2000 | S |
| 6142939 | Eppstein et al. | Nov 2000 | A |
| 6142972 | Chiekh et al. | Nov 2000 | A |
| 6152898 | Olsen | Nov 2000 | A |
| 6155824 | Kamen et al. | Dec 2000 | A |
| 6165154 | Gray et al. | Dec 2000 | A |
| 6168609 | Kamen et al. | Jan 2001 | B1 |
| 6175752 | Say et al. | Jan 2001 | B1 |
| 6183434 | Eppstein | Feb 2001 | B1 |
| 6183441 | Kriesel et al. | Feb 2001 | B1 |
| 6186982 | Gross et al. | Feb 2001 | B1 |
| 6190359 | Heruth | Feb 2001 | B1 |
| 6191102 | DiMarchi et al. | Feb 2001 | B1 |
| 6193704 | Winters | Feb 2001 | B1 |
| 6202708 | Bynum | Mar 2001 | B1 |
| 6203528 | Deckert et al. | Mar 2001 | B1 |
| 6206850 | Veech | Mar 2001 | B1 |
| 6207856 | Veech | Mar 2001 | B1 |
| 6210361 | Kamen et al. | Apr 2001 | B1 |
| 6213943 | Abreu | Apr 2001 | B1 |
| 6214617 | Herman | Apr 2001 | B1 |
| 6223130 | Gray et al. | Apr 2001 | B1 |
| 6261280 | Houben et al. | Apr 2001 | B1 |
| 6228060 | Howell | May 2001 | B1 |
| 6231545 | Kriesel et al. | May 2001 | B1 |
| 6234997 | Kamen et al. | May 2001 | B1 |
| 6241704 | Peterson et al. | Jun 2001 | B1 |
| 6248067 | Causey, III et al. | Jun 2001 | B1 |
| 6248093 | Moberg | Jun 2001 | B1 |
| 6251098 | Rake et al. | Jun 2001 | B1 |
| 6253804 | Safabash | Jul 2001 | B1 |
| 6254586 | Mann et al. | Jul 2001 | B1 |
| 6259587 | Sheldon et al. | Jul 2001 | B1 |
| 6261272 | Gross et al. | Jul 2001 | B1 |
| 6267564 | Rapheal | Jul 2001 | B1 |
| D446854 | Cheney, II et al. | Aug 2001 | S |
| 6270478 | Mernøe | Aug 2001 | B1 |
| 6280416 | Van Antwerp et al. | Aug 2001 | B1 |
| 6283943 | Dy et al. | Sep 2001 | B1 |
| 6283944 | McMullen et al. | Sep 2001 | B1 |
| 6284725 | Coolidge et al. | Sep 2001 | B1 |
| 6284727 | Kim et al. | Sep 2001 | B1 |
| 6287294 | Lemelson | Sep 2001 | B1 |
| 6287521 | Quay et al. | Sep 2001 | B1 |
| 6293925 | Safabash et al. | Sep 2001 | B1 |
| 6302653 | Bryant et al. | Oct 2001 | B1 |
| 6302990 | Nelson | Oct 2001 | B1 |
| 6306420 | Cheikh et al. | Oct 2001 | B1 |
| 6312393 | Abreu | Nov 2001 | B1 |
| 6315769 | Peer et al. | Nov 2001 | B1 |
| 6316038 | Veech | Nov 2001 | B1 |
| 6319540 | Van Antwerp et al. | Nov 2001 | B1 |
| 6321597 | Demers et al. | Nov 2001 | B1 |
| 6323237 | Veech | Nov 2001 | B1 |
| 6329336 | Bridon et al. | Dec 2001 | B1 |
| 6334856 | Allen et al. | Jan 2002 | B1 |
| 6338730 | Bonutti et al. | Jan 2002 | B1 |
| D453830 | McDowell et al. | Feb 2002 | S |
| 6343614 | Gray et al. | Feb 2002 | B1 |
| 6346095 | Gross et al. | Feb 2002 | B1 |
| 6348043 | Hagen et al. | Feb 2002 | B1 |
| 6355019 | Kriesel et al. | Mar 2002 | B1 |
| 6355021 | Nielson et al. | Mar 2002 | B1 |
| 6360888 | McIvor et al. | Mar 2002 | B1 |
| 6362591 | Moberg | Mar 2002 | B1 |
| 6364279 | Neftel et al. | Apr 2002 | B1 |
| 6364857 | Gray et al. | Apr 2002 | B1 |
| 6368274 | Van Antwerp et al. | Apr 2002 | B1 |
| 6374876 | Bynum | Apr 2002 | B2 |
| 6375459 | Kamen et al. | Apr 2002 | B1 |
| 6375638 | Nason et al. | Apr 2002 | B2 |
| 6379345 | Constantz | Apr 2002 | B1 |
| 6414018 | Duhaylongsod | Apr 2002 | B1 |
| 6416293 | Bouchard et al. | Apr 2002 | B1 |
| 6423001 | Abreu | Apr 2002 | B1 |
| 6423035 | Das et al. | Apr 2002 | B1 |
| 6427088 | Bowman, IV et al. | Apr 2002 | B1 |
| 6382923 | Gray | May 2002 | B1 |
| 6394981 | Heruth | May 2002 | B2 |
| 6403558 | Moses et al. | Jun 2002 | B1 |
| 6406455 | Willis et al. | Jun 2002 | B1 |
| 6416495 | Kriesel et al. | Jul 2002 | B1 |
| 6416496 | Rogers et al. | Jul 2002 | B1 |
| 6422057 | Anderson | Jul 2002 | B1 |
| 6424847 | Mastrototaro et al. | Jul 2002 | B1 |
| D461241 | Moberg et al. | Aug 2002 | S |
| D461891 | Moberg | Aug 2002 | S |
| 6429197 | Coolidge et al. | Aug 2002 | B1 |
| 6432383 | Modi | Aug 2002 | B1 |
| 6436072 | Kullas et al. | Aug 2002 | B1 |
| 6440933 | Bodor et al. | Aug 2002 | B1 |
| 6443942 | Van Antwerp et al. | Sep 2002 | B2 |
| 6453956 | Safabash | Sep 2002 | B2 |
| 6458102 | Mann et al. | Oct 2002 | B1 |
| 6458355 | Hsei et al. | Oct 2002 | B1 |
| 6461329 | Van Antwerp et al. | Oct 2002 | B1 |
| 6461331 | Van Antwerp | Oct 2002 | B1 |
| 6464667 | Kamen et al. | Oct 2002 | B1 |
| 6464671 | Elver et al. | Oct 2002 | B1 |
| 6465431 | Thorn et al. | Oct 2002 | B1 |
| 6468532 | Hsei et al. | Oct 2002 | B1 |
| 6471436 | Gjata et al. | Oct 2002 | B1 |
| 6471674 | Emig et al. | Oct 2002 | B1 |
| 6475180 | Peterson et al. | Nov 2002 | B2 |
| 6475196 | Vachon | Nov 2002 | B1 |
| 6485263 | Bryant et al. | Nov 2002 | B1 |
| 6485461 | Mason et al. | Nov 2002 | B1 |
| 6485465 | Moberg et al. | Nov 2002 | B2 |
| 6495366 | Briggs | Dec 2002 | B1 |
| 6495532 | Bathurst et al. | Dec 2002 | B1 |
| 6500150 | Gross et al. | Dec 2002 | B1 |
| 6503184 | Ni et al. | Jan 2003 | B1 |
| 6503231 | Prausnitz et al. | Jan 2003 | B1 |
| 6505059 | Kollias et al. | Jan 2003 | B1 |
| 6512939 | Colvin et al. | Jan 2003 | B1 |
| 6514500 | Bridon et al. | Feb 2003 | B1 |
| 6520326 | McIvor et al. | Feb 2003 | B2 |
| 6520747 | Gray et al. | Feb 2003 | B2 |
| 6520936 | Mann | Feb 2003 | B1 |
| 6520938 | Funderbunk et al. | Feb 2003 | B1 |
| D471352 | Shetler et al. | Mar 2003 | S |
| 6527716 | Eppstein | Mar 2003 | B1 |
| 6530900 | Daily et al. | Mar 2003 | B1 |
| 6537268 | Gibson et al. | Mar 2003 | B1 |
| 6544193 | Abreu | Apr 2003 | B2 |
| 6544229 | Danby et al. | Apr 2003 | B1 |
| 6551276 | Mann et al. | Apr 2003 | B1 |
| 6554798 | Mann et al. | Apr 2003 | B1 |
| 6554800 | Nezhadian et al. | Apr 2003 | B1 |
| 6555986 | Moberg | Apr 2003 | B2 |
| 6554343 | Neftel et al. | May 2003 | B2 |
| 6558320 | Causey, III et al. | May 2003 | B1 |
| 6558345 | Houben et al. | May 2003 | B1 |
| 6558351 | Steil et al. | May 2003 | B1 |
| 6560471 | Heller et al. | May 2003 | B1 |
| 6562001 | Lebel et al. | May 2003 | B2 |
| 6564105 | Starkweather et al. | May 2003 | B2 |
| 6565509 | Say et al. | May 2003 | B1 |
| 6565531 | Mori et al. | May 2003 | B1 |
| 6565535 | Zaias et al. | May 2003 | B2 |
| 6565885 | Tarara et al. | May 2003 | B1 |
| 6571128 | Lebel et al. | May 2003 | B2 |
| 6572586 | Wojcik | Jun 2003 | B1 |
| 6577899 | Lebel et al. | Jun 2003 | B2 |
| 6579690 | Bonnecaze et al. | Jun 2003 | B1 |
| 6585644 | Lebel et al. | Jul 2003 | B2 |
| 6585695 | Adair et al. | Jul 2003 | B1 |
| 6586401 | Thorn et al. | Jul 2003 | B1 |
| 6589936 | Thorn et al. | Jul 2003 | B1 |
| 6591876 | Safabash | Jul 2003 | B2 |
| 6593295 | Bridon et al. | Jul 2003 | B2 |
| 6595202 | Ganan-Calvo et al. | Jul 2003 | B2 |
| 6595756 | Gray et al. | Jul 2003 | B2 |
| 6595956 | Gross et al. | Jul 2003 | B1 |
| 6604908 | Bryant et al. | Aug 2003 | B1 |
| 6607509 | Bobroff et al. | Aug 2003 | B2 |
| 6608101 | Ni et al. | Aug 2003 | B1 |
| 6610288 | Edge et al. | Aug 2003 | B1 |
| 6611707 | Prausnilz et al. | Aug 2003 | B1 |
| 6613026 | Palasis et al. | Sep 2003 | B1 |
| 6613038 | Bonutti et al. | Sep 2003 | B2 |
| 6616627 | Willis et al. | Sep 2003 | B2 |
| 6617450 | Stocker et al. | Sep 2003 | B1 |
| 6622732 | Constantz | Sep 2003 | B2 |
| 6503062 | Gray et al. | Oct 2003 | B1 |
| 6629954 | Heruth | Oct 2003 | B1 |
| 6632215 | Lemelson | Oct 2003 | B1 |
| 6635049 | Robinson et al. | Oct 2003 | B1 |
| 6635743 | Ebner et al. | Oct 2003 | B1 |
| 6641533 | Causey, III et al. | Nov 2003 | B2 |
| 6642015 | Vachon et al. | Nov 2003 | B2 |
| 6645175 | Kriesel et al. | Nov 2003 | B2 |
| 6648821 | Lebel et al. | Nov 2003 | B2 |
| 6651656 | Demers et al. | Nov 2003 | B2 |
| 6652493 | Das | Nov 2003 | B1 |
| 6652510 | Lord et al. | Nov 2003 | B2 |
| 6653283 | Moses | Nov 2003 | B1 |
| 6656148 | Das et al. | Dec 2003 | B2 |
| 6656158 | Mahoney et al. | Dec 2003 | B2 |
| 6656159 | Flaherty | Dec 2003 | B2 |
| 6659948 | Lebel et al. | Dec 2003 | B2 |
| 6659982 | Douglas et al. | Dec 2003 | B2 |
| 6660509 | Herman et al. | Dec 2003 | B1 |
| 6663359 | Gray | Dec 2003 | B2 |
| 6665909 | Collins et al. | Dec 2003 | B2 |
| 6666845 | Hooper et al. | Dec 2003 | B2 |
| 6669663 | Thompson | Dec 2003 | B1 |
| 6669668 | Kleeman et al. | Dec 2003 | B1 |
| 6669669 | Flaherty et al. | Dec 2003 | B2 |
| 6671554 | Gibson et al. | Dec 2003 | B2 |
| 6685664 | Levin et al. | Feb 2004 | B2 |
| 6687546 | Lebel et al. | Feb 2004 | B2 |
| 6689073 | Quay | Feb 2004 | B2 |
| 6689100 | Connelly et al. | Feb 2004 | B2 |
| 6689108 | Lavi et al. | Feb 2004 | B2 |
| 6689607 | Ni et al. | Feb 2004 | B2 |
| 6689747 | Filvaroff et al. | Feb 2004 | B2 |
| 6692456 | Eppstein et al. | Feb 2004 | B1 |
| 6692457 | Flaherty | Feb 2004 | B2 |
| 6694191 | Starkweather et al. | Feb 2004 | B2 |
| 6699218 | Flaherty et al. | Mar 2004 | B2 |
| 6699219 | Emig et al. | Mar 2004 | B2 |
| 6702779 | Connelly et al. | Mar 2004 | B2 |
| 6703217 | Herman et al. | Mar 2004 | B2 |
| 6709417 | Houle et al. | Mar 2004 | B1 |
| 6711436 | Duhaylongsod | Mar 2004 | B1 |
| 6716190 | Glines et al. | Apr 2004 | B1 |
| 6716193 | Neftel | Apr 2004 | B1 |
| 6721582 | Trepagnier et al. | Apr 2004 | B2 |
| 6723072 | Flaherty et al. | Apr 2004 | B2 |
| 6726656 | Kamen et al. | Apr 2004 | B2 |
| 6728560 | Kollias et al. | Apr 2004 | B2 |
| 6733446 | Lebel et al. | May 2004 | B2 |
| 6734162 | Van Antwerp et al. | May 2004 | B2 |
| 6734186 | Maw et al. | May 2004 | B1 |
| 6736795 | Michel | May 2004 | B2 |
| 6737401 | Kim et al. | May 2004 | B2 |
| 6740059 | Flaherty | May 2004 | B2 |
| 6740072 | Starkweather et al. | May 2004 | B2 |
| 6740075 | Lebel et al. | May 2004 | B2 |
| 6740655 | Magee et al. | May 2004 | B2 |
| 6749403 | Bryant et al. | Jun 2004 | B2 |
| 6749587 | Flaherty | Jun 2004 | B2 |
| 6750311 | Van Antwerp et al. | Jun 2004 | B1 |
| 6752299 | Shetler et al. | Jun 2004 | B2 |
| 6752785 | Van Antwerp et al. | Jun 2004 | B2 |
| 6752787 | Causey, III et al. | Jun 2004 | B1 |
| 6753177 | Stocker et al. | Jun 2004 | B1 |
| 6753328 | Wands et al. | Jun 2004 | B2 |
| 6755811 | Constantz | Jun 2004 | B1 |
| 6758810 | Lebel et al. | Jul 2004 | B2 |
| 6766183 | Walsh et al. | Jul 2004 | B2 |
| 6768425 | Flaherty et al. | Jul 2004 | B2 |
| 6770067 | Lorenzen et al. | Aug 2004 | B2 |
| 6770729 | Van Antwerp | Aug 2004 | B2 |
| 6774120 | Ferber | Aug 2004 | B1 |
| 6784274 | Van Antwerp et al. | Aug 2004 | B2 |
| 6792982 | Lincoln et al. | Sep 2004 | B2 |
| 6795956 | Hartlaub et al. | Sep 2004 | B2 |
| 6796957 | Carpenter et al. | Sep 2004 | B2 |
| 6800071 | McConnell et al. | Oct 2004 | B1 |
| 6800663 | Asgarzadeh et al. | Oct 2004 | B2 |
| 6801420 | Talbot et al. | Oct 2004 | B2 |
| 6804544 | Van Antwerp et al. | Oct 2004 | B2 |
| 6805687 | Dextraseur et al. | Oct 2004 | B2 |
| 6805693 | Gray et al. | Oct 2004 | B2 |
| 6808369 | Gray et al. | Oct 2004 | B2 |
| 6808506 | Lastovich et al. | Oct 2004 | B2 |
| 6809507 | Morgan et al. | Oct 2004 | B2 |
| 6809563 | Mann et al. | Oct 2004 | B2 |
| 6810290 | Lebel et al. | Oct 2004 | B2 |
| 6811533 | Lebel et al. | Nov 2004 | B2 |
| 6811534 | Bowman, IV et al. | Nov 2004 | B2 |
| 6813519 | Lebel et al. | Nov 2004 | B2 |
| 6814715 | Bonutti et al. | Nov 2004 | B2 |
| 6817990 | Yap et al. | Nov 2004 | B2 |
| 6821949 | Bridon et al. | Nov 2004 | B2 |
| 6824529 | Gross et al. | Nov 2004 | B2 |
| 6827702 | Lebel et al. | Dec 2004 | B2 |
| 6830558 | Flaherty et al. | Dec 2004 | B2 |
| 6830564 | Gray | Dec 2004 | B2 |
| 6840922 | Nielsen et al. | Jan 2005 | B2 |
| 6843782 | Gross et al. | Jan 2005 | B2 |
| 6849718 | Kaelin, Jr. et al. | Feb 2005 | B2 |
| 6849719 | Shi et al. | Feb 2005 | B2 |
| 6902544 | Ludin et al. | Jun 2005 | B2 |
| 6936029 | Mann et al. | Aug 2005 | B2 |
| 6939324 | Gonnelli et al. | Sep 2005 | B2 |
| 6960184 | Willis et al. | Nov 2005 | B2 |
| 6979316 | Rubin et al. | Dec 2005 | B1 |
| 7011234 | Stradella | Mar 2006 | B2 |
| 7014625 | Bengtsson | Mar 2006 | B2 |
| 7022107 | Christensen et al. | Apr 2006 | B1 |
| 7108686 | Burke et al. | Sep 2006 | B2 |
| 7150409 | Gonnelli et al. | Dec 2006 | B2 |
| 7204823 | Estes et al. | Apr 2007 | B2 |
| 7250037 | Shermer et al. | Jul 2007 | B2 |
| 7337922 | Rake et al. | Mar 2008 | B2 |
| 7367968 | Rosenberg et al. | May 2008 | B2 |
| 7481792 | Gonnelli et al. | Jan 2009 | B2 |
| 7530968 | Gonnelli | May 2009 | B2 |
| 7534226 | Mernoe et al. | May 2009 | B2 |
| 7678079 | Shermer et al. | Mar 2010 | B2 |
| 20010005781 | Bergens et al. | Jun 2001 | A1 |
| 20010010238 | Bynum | Aug 2001 | A1 |
| 20010016710 | Nason et al. | Aug 2001 | A1 |
| 20010027287 | Shmulewitz et al. | Oct 2001 | A1 |
| 20010031944 | Peterson et al. | Oct 2001 | A1 |
| 20010037083 | Hartlaub et al. | Nov 2001 | A1 |
| 20010053891 | Ackley | Dec 2001 | A1 |
| 20020004015 | Carlisle et al. | Jan 2002 | A1 |
| 20020019612 | Watanabe et al. | Feb 2002 | A1 |
| 20020040208 | Flaherty et al. | Apr 2002 | A1 |
| 20020045867 | Nielsen et al. | Apr 2002 | A1 |
| 20020055460 | Coolidge et al. | May 2002 | A1 |
| 20020061838 | Holmquist et al. | May 2002 | A1 |
| 20020072733 | Flaherty | Jun 2002 | A1 |
| 20020077599 | Wojcik | Jun 2002 | A1 |
| 20020091358 | Klitmose | Jul 2002 | A1 |
| 20020095124 | Palasis et al. | Jul 2002 | A1 |
| 20020123716 | VanDiver et al. | Sep 2002 | A1 |
| 20020123740 | Flaherty et al. | Sep 2002 | A1 |
| 20020128594 | Das et al. | Sep 2002 | A1 |
| 20020138049 | Allen et al. | Sep 2002 | A1 |
| 20020147131 | Collidge et al. | Oct 2002 | A1 |
| 20020151842 | Gonnelli et al. | Oct 2002 | A1 |
| 20020151846 | Christenson et al. | Oct 2002 | A1 |
| 20020156418 | Gonnelli et al. | Oct 2002 | A1 |
| 20020156464 | Blischak et al. | Oct 2002 | A1 |
| 20020169416 | Gonnelli | Nov 2002 | A1 |
| 20020177809 | Kriesel et al. | Nov 2002 | A1 |
| 20020183693 | Peterson et al. | Dec 2002 | A1 |
| 20020188259 | Hickle et al. | Dec 2002 | A1 |
| 20020198493 | Diaz et al. | Dec 2002 | A1 |
| 20020198494 | Diaz et al. | Dec 2002 | A1 |
| 20030009133 | Ramey | Jan 2003 | A1 |
| 20030022823 | Efendic | Jan 2003 | A1 |
| 20030024508 | Hellar et al. | Feb 2003 | A1 |
| 20030050237 | Kim et al. | Mar 2003 | A1 |
| 20030073626 | Hathaway et al. | Apr 2003 | A1 |
| 20030100888 | Spinello | May 2003 | A1 |
| 20030125669 | Safabash et al. | Jul 2003 | A1 |
| 20030130619 | Safabash et al. | Jul 2003 | A1 |
| 20030130647 | Gray et al. | Jul 2003 | A1 |
| 20030135158 | Gonnelli | Jul 2003 | A1 |
| 20030135160 | Gray et al. | Jul 2003 | A1 |
| 20030158520 | Safabash et al. | Aug 2003 | A1 |
| 20030167039 | Moberg | Sep 2003 | A1 |
| 20030195157 | Natarajan et al. | Oct 2003 | A1 |
| 20030199445 | Knudsen et al. | Oct 2003 | A1 |
| 20030199823 | Bobroff et al. | Oct 2003 | A1 |
| 20030050623 | Lord et al. | Nov 2003 | A1 |
| 20030212000 | Van Antwerp | Nov 2003 | A1 |
| 20030216714 | Gill | Nov 2003 | A1 |
| 20030220610 | Lastovich et al. | Nov 2003 | A1 |
| 20030225373 | Bobroff et al. | Dec 2003 | A1 |
| 20030229309 | Babkes et al. | Dec 2003 | A1 |
| 20030233069 | Gillespie et al. | Dec 2003 | A1 |
| 20040002682 | Kovelman et al. | Jan 2004 | A1 |
| 20040029784 | Hathaway | Feb 2004 | A1 |
| 20040064086 | Gottlieb et al. | Apr 2004 | A1 |
| 20040064096 | Flaherty et al. | Apr 2004 | A1 |
| 20040064097 | Peterson | Apr 2004 | A1 |
| 20040073161 | Tachibana | Apr 2004 | A1 |
| 20040077000 | Stocker et al. | Apr 2004 | A1 |
| 20040085215 | Moberg et al. | May 2004 | A1 |
| 20040091374 | Gray | May 2004 | A1 |
| 20040092873 | Moberg | May 2004 | A1 |
| 20040092893 | Haider et al. | May 2004 | A1 |
| 20040094823 | Matsuno | May 2004 | A1 |
| 20040115067 | Rush et al. | Jun 2004 | A1 |
| 20040116905 | Pedersen et al. | Jun 2004 | A1 |
| 20040126372 | Banerjee et al. | Jul 2004 | A1 |
| 20040126373 | Banerjee et al. | Jul 2004 | A1 |
| 20040133163 | Schiffmann | Jul 2004 | A1 |
| 20040143216 | Douglas et al. | Jul 2004 | A1 |
| 20040143217 | Michel | Jul 2004 | A1 |
| 20040143218 | Das | Jul 2004 | A1 |
| 20040153032 | Garribotto et al. | Aug 2004 | A1 |
| 20040155079 | Shetler et al. | Aug 2004 | A1 |
| 20040167464 | Ireland et al. | Aug 2004 | A1 |
| 20040167470 | Emig et al. | Aug 2004 | A1 |
| 20040176725 | Stutz et al. | Sep 2004 | A1 |
| 20040209801 | Brand et al. | Oct 2004 | A1 |
| 20040220456 | Eppstein | Nov 2004 | A1 |
| 20040220525 | Willis et al. | Nov 2004 | A1 |
| 20040225281 | Lorenzen et al. | Nov 2004 | A1 |
| 20040247445 | Nelson et al. | Dec 2004 | A1 |
| 20040249363 | Burke et al. | Dec 2004 | A1 |
| 20040250382 | Collins et al. | Dec 2004 | A1 |
| 20040254525 | Uber et al. | Dec 2004 | A1 |
| 20040260234 | Srinivasan et al. | Dec 2004 | A1 |
| 20040266678 | Beeley et al. | Dec 2004 | A1 |
| 20040267201 | Agerup | Dec 2004 | A1 |
| 20050008661 | Fereira et al. | Jan 2005 | A1 |
| 20050033232 | Kriesel | Feb 2005 | A1 |
| 20050038387 | Kriesel et al. | Feb 2005 | A1 |
| 20050054988 | Rosenberg et al. | Mar 2005 | A1 |
| 20050065472 | Cindrich et al. | Mar 2005 | A1 |
| 20050070875 | Kulessa | Mar 2005 | A1 |
| 20050112188 | Eliaz et al. | May 2005 | A1 |
| 20050119618 | Gonnelli | Jun 2005 | A1 |
| 20050137530 | Campbell et al. | Jun 2005 | A1 |
| 20050137578 | Heruth et al. | Jun 2005 | A1 |
| 20050171477 | Rubin et al. | Aug 2005 | A1 |
| 20050171512 | Flaherty | Aug 2005 | A1 |
| 20050177109 | Azzolini | Aug 2005 | A1 |
| 20050024175 | Gray et al. | Sep 2005 | A1 |
| 20050215850 | Klein et al. | Sep 2005 | A1 |
| 20050245904 | Estes et al. | Nov 2005 | A1 |
| 20050273083 | Lebel et al. | Dec 2005 | A1 |
| 20050277912 | John | Dec 2005 | A1 |
| 20050278073 | Roth | Dec 2005 | A1 |
| 20060030838 | Gonnelli | Feb 2006 | A1 |
| 20060069382 | Pedersen | Mar 2006 | A1 |
| 20060079862 | Genosar | Apr 2006 | A1 |
| 20060100578 | Lieberman | May 2006 | A1 |
| 20060122628 | Solar et al. | Jun 2006 | A1 |
| 20060150747 | Mallet | Jul 2006 | A1 |
| 20060184119 | Remde et al. | Aug 2006 | A1 |
| 20060184154 | Moberg et al. | Aug 2006 | A1 |
| 20060189939 | Gonnelli | Aug 2006 | A1 |
| 20060200112 | Paul | Sep 2006 | A1 |
| 20060264831 | Skwarek et al. | Nov 2006 | A1 |
| 20060264835 | Nielsen et al. | Nov 2006 | A1 |
| 20070016170 | Kovelman | Jan 2007 | A1 |
| 20070060894 | Dai et al. | Mar 2007 | A1 |
| 20070073236 | Mernoe et al. | Mar 2007 | A1 |
| 20070088268 | Edwards | Apr 2007 | A1 |
| 20070100283 | Causey, III et al. | May 2007 | A1 |
| 20070149925 | Edwards et al. | Jun 2007 | A1 |
| 20070167912 | Causey et al. | Jul 2007 | A1 |
| 20070173761 | Kanderian, Jr. et al. | Jul 2007 | A1 |
| 20070179444 | Causey et al. | Aug 2007 | A1 |
| 20070239114 | Edwards et al. | Oct 2007 | A1 |
| 20070287958 | McKenzie et al. | Dec 2007 | A1 |
| 20070287985 | Estes et al. | Dec 2007 | A1 |
| 20080058719 | Edwards et al. | Mar 2008 | A1 |
| 20080091176 | Alessi et al. | Apr 2008 | A1 |
| 20080106431 | Blomquist | May 2008 | A1 |
| 20080125701 | Moberg et al. | May 2008 | A1 |
| 20080139910 | Mastrototaro et al. | Jun 2008 | A1 |
| 20080183060 | Steil et al. | Jul 2008 | A1 |
| 20080215006 | Thorkild | Sep 2008 | A1 |
| 20080249468 | Edwards et al. | Oct 2008 | A1 |
| 20080306436 | Edwards et al. | Dec 2008 | A1 |
| 20080312512 | Brukalo et al. | Dec 2008 | A1 |
| 20080319383 | Byland et al. | Dec 2008 | A1 |
| 20090054867 | Gravesen et al. | Feb 2009 | A1 |
| 20090062747 | Saul | Mar 2009 | A1 |
| 20090088689 | Carter | Apr 2009 | A1 |
| 20090088692 | Adams et al. | Apr 2009 | A1 |
| 20090093772 | Genosar et al. | Apr 2009 | A1 |
| 20090182277 | Carter | Jul 2009 | A1 |
| 20090202608 | Allessi et al. | Aug 2009 | A1 |
| 20090220358 | Krivsky et al. | Sep 2009 | A1 |
| 20090240232 | Gonnelli et al. | Sep 2009 | A1 |
| 20090247982 | Krulevitch et al. | Oct 2009 | A1 |
| 20090281528 | Grovender et al. | Nov 2009 | A1 |
| 20110056259 | Mielonen et al. | Mar 2011 | A1 |
| Number | Date | Country |
|---|---|---|
| 2563988 | May 1989 | AU |
| 3634725 | Apr 1998 | DE |
| 3739657 | May 1998 | DE |
| 0028557 | Apr 1985 | EP |
| 0209677 | Jan 1987 | EP |
| 0401179 | Dec 1990 | EP |
| 0513879 | Nov 1992 | EP |
| 0098592 | Jan 1994 | EP |
| 0638324 | Feb 1995 | EP |
| 0937475 | Aug 1999 | EP |
| 0902696 | Mar 2002 | EP |
| 1173197 | Dec 2004 | EP |
| 1512410 | Mar 2005 | EP |
| 1210136 | Jan 2006 | EP |
| 2054381 | Feb 1981 | GB |
| 62-079067 | Apr 1987 | JP |
| 6227016 | Nov 1987 | JP |
| 62270167 | Nov 1987 | JP |
| 10-506827 | Jul 1998 | JP |
| 2000-262525 | Sep 2000 | JP |
| 2002-098765 | Dec 2002 | JP |
| 2002-355317 | Dec 2002 | JP |
| 06-507828 | Mar 2006 | JP |
| 2006-524555 | Nov 2006 | JP |
| 7310455 | Feb 1974 | NL |
| 2248223 | Mar 2005 | RU |
| 1055518 | Nov 1983 | SU |
| 199728835 | Aug 1997 | WO |
| 1985003232 | Jan 1998 | WO |
| 199808871 | Mar 1998 | WO |
| 1998010129 | Dec 1998 | WO |
| 199947161 | Sep 1999 | WO |
| 1999048546 | Sep 1999 | WO |
| 20066138 | Nov 2000 | WO |
| 200066142 | Nov 2000 | WO |
| 200100223 | Jan 2001 | WO |
| 200187322 | Nov 2001 | WO |
| 2002085406 | Oct 2002 | WO |
| 2003008023 | Jan 2003 | WO |
| 2003050846 | Jun 2003 | WO |
| 2003061362 | Jul 2003 | WO |
| 2003080160 | Oct 2003 | WO |
| 2004037195 | May 2004 | WO |
| 2004089335 | Oct 2004 | WO |
| 2004094823 | Nov 2004 | WO |
| 2004094823 | Nov 2004 | WO |
| WO-2004094823 | Nov 2004 | WO |
| WO 2004094823 | Nov 2004 | WO |
| 2004094823 | Feb 2005 | WO |
| 2005046716 | May 2005 | WO |
| 2005048952 | Jun 2005 | WO |
| 2005060986 | Jul 2005 | WO |
| 2007051139 | May 2007 | WO |
| 2007129317 | Nov 2007 | WO |
| 2008036509 | Mar 2008 | WO |
| 2008139458 | Nov 2008 | WO |
| 2009013735 | Jan 2009 | WO |
| 2009016637 | Feb 2009 | WO |
| 2009081403 | Jul 2009 | WO |
| 2009125398 | Oct 2009 | WO |
| Entry |
|---|
| Examiner's First Report on Australian Patent Application No. 2011210473 dated Feb. 14, 2012. |
| Office Action for U.S. Appl. No. 12/336,395 dated Sep. 21, 2011. |
| Notification of Reasons for Rejection in Japanese Patent Application No. 2009-503245. |
| Supplementary European Search Report for European Patent Application No. EP 07 75 9578 dated Dec. 7, 2011. |
| Decision of Grant for Russian Patent Application No. 2008143015 dated Jul. 6, 2011. |
| International Search Report and Written Opinion dated Dec. 10, 2010 in connection with International Application No. PCT/US10/52352. |
| English Translation of First Office Action issued in connection with Chinese Application No. 200780020245.9. |
| First EPO Examination Report issued in connection with European Application No. 0198824.2. |
| Gappa, et al., The effect of zinc-crystallized glucagon-like peptide-1 on insulin secretion of macroencapsulated pancreatic islets. Tissue Eng. 7(1): 35-44, 2001. |
| Haak, New developments in the treatment of type 1 diabetes mellitus. Exp. Clin Endocrinol Diabetes. 107 Suppl 3: S108-13, 1999. |
| Holst et al., On the treatment of diabetes mellitus with glucagon-like peptide-1. Ann N Y Acad Sci. 865: 336-43, 1998. |
| Hui et al., The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. Eur J. Endocrinol. 146(6): 863-9, 2002. |
| Joseph et al., Oral delivery of glucagon-like peptide-1 in a modified polymer preparation normalizes basal glycaemia in diabetic db/db mice. Diabetologia. 43(10): 1319-28, 2000. |
| Toft-Nielson et al., Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care. 22(7): 1137-43, 1999. |
| Wang et al., Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. J Clin Invest. 99(12): 2883-9, 1997. |
| Office action from U.S. Appl. No. 11/175,990 dated Nov. 10, 2009. |
| Office action from U.S. Appl. No. 11/175,990 dated Jan. 19, 2007. |
| Office action from U.S. Appl. No. 11/175,990 dated Oct. 2, 2007. |
| Office action from U.S. Appl. No. 11/175,990 dated Jan. 29, 2009. |
| Office action from U.S. Appl. No. 10/831,354 dated Sep. 18, 2006. |
| Office action from U.S. Appl. No. 10/831,354 dated May 4, 2007. |
| Office action from U.S. Appl. No. 10/831,354 dated Jul. 31, 2008. |
| Office action from U.S. Appl. No. 10/831,354 dated Mar. 23, 2009. |
| Singapore Written Opinion from Singapore Pat. App. No. 2008070302-5 dated Jan. 6, 2010. |
| Gonnelli, Robert R. Barnett International Needle-Free Injection Systems presentation materials, Mar. 25, 2004, BioValve Technologies, Inc. (10 pages). |
| Banks et al., Brain uptake of the glucagon-like peptide-1 antagonist exendin(9-39) after intranasal administration. J Pharmacol Exp Ther. 309(s): 469-75, 2004. |
| Capaldi, Treatments and devices for future diabetes management. Nurs Times. 101(18): 30-2, 2005. |
| Choi et al., Control of blood glucose by novel GLP-1 delivery using biodegradable triblock copolymer of PLGA-PEG-PLGA in types 2 diabetic rats. Pharm Res. 21(5): 827-31, 2004. |
| Donahey et al., Intraventricular GLP-1 reduces short-but not long-term food intake or body weight in lean and obese rats. Brain Res. 779(1-2): 75-83, 1998. |
| Drucker, Development of glucagon-like peptide-1 based pharmaceuticals as therapeutic agents for the treatment of diabetes. Curr Pharm Des. 7(14): 1399-412, 2001. |
| Notification of Reasons for Rejection dated Dec. 3, 2013 for Japanese Patent Application No. 2012-255233. |
| Number | Date | Country | |
|---|---|---|---|
| 20180028743 A1 | Feb 2018 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60787616 | Mar 2006 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 14341879 | Jul 2014 | US |
| Child | 15597981 | US | |
| Parent | 13719481 | Dec 2012 | US |
| Child | 14341879 | US | |
| Parent | 13013379 | Jan 2011 | US |
| Child | 13719481 | US | |
| Parent | 12295173 | US | |
| Child | 13013379 | US |
